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Abstract            
Cachexia, a condition prevalent in many chronically-ill patients, is characterized by 
weight loss and fatigue resulting from decreases in muscle mass and function. Although 
development of cachexia is associated with tumour-burden and disease-related malnutrition, 
studies have suggested a causative link between chemotherapy and cachexia. Day 4 myotubes 
were treated with vehicle or a chemotherapy drug cocktail consisting of cisplatin, 5-fluourouracil 
and leucovorin. Myotubes treated with the drug cocktail showed irregular myotube structure and 
reductions in myofibrillar protein content. Myotubes treated with the drug cocktail showed 
reductions in the phosphorylation of AKTSer473, S6Ser235/236 and S6K1Thr389. Drug treatments also 
led to reductions in protein synthesis and mitochondrial complexes cytochrome C oxidase and 
succinate dehydrogenase. Lastly, reductions in insulin stimulated glucose uptake were found 
following drug treatment. Findings suggest that it is critical to identify interventions that limit the 
negative effects of these drugs on muscle protein status and mitochondrial content.  
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Chapter One: Introduction        
 Cachexia, a condition affecting approximately nine million patients with chronic disease 
today68, is characterized by detrimental loss of body weight and depletion of fat and muscle 
mass. In addition, this muscle wasting syndrome leads to wide scale fatigue and weakness, 
associated with decreases in quality of life and increased mortality and morbidity183, 184.  
 Maintenance of skeletal muscle mass is dependent on a balance between protein synthesis 
and protein degradation. These two processes are highly regulated by multiple signalling events 
and pathways within skeletal muscle. For example, activation of the insulin receptor substrate 1 
(IRS-1)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway is well-
known to be vital for skeletal muscle growth and the inhibition of skeletal muscle protein 
degradation185. In opposition, stimulation of either the ubiquitin proteasome pathway (UPP) or 
autophagic mechanisms induce protein degradation within skeletal muscle186. Although upstream 
activators of the UPP, such as forkhead box protein O (FOXO) or nuclear factor kappa-light-
chain-enhancer of activated B cells (NFKB) are upregulated in atrophic conditions such as 
cachexia, signalling events and mechanisms in these pathways are yet to be completely 
understood.            
 Past reports have suggested that the development and severity of cachexia is due to the 
administration of cytotoxic and antineoplastic chemotherapy drugs. Symptoms including nausea, 
vomiting, poor nutrition and anorexia-like states are often present following chemotherapy 
treatment. Of these, no side effect matches the debilitating loss of muscle strength and mass, 
often accompanying chemotherapy regimens in patients.     
 Although available evidence suggests an association between chemotherapy treatment 
and cachexia, the mechanisms of chemotherapeutic regimens in the promotion of cachectic 
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symptoms are not completely clear. Cisplatin, a platinum-containing chemotherapeutic, used in 
the treatment of testicular, ovarian, head, lung and neck cancers, dramatically increases muscle 
atrophy F-box (MAFbx) and muscle ring finger-1 (MuRF1) in vivo158. In addition, cisplatin also 
activates nuclear factor kappa-light-chain enhancer of activated B cells (Nf-KB)159, linking this 
chemotherapeutic to the upregulation of the ubiquitin proteasome pathway (UPP) in muscle.     
5-Fluourouracil (5-Flu), an antineoplastic agent part of Folfiri and Folfox chemotherapy 
regimens, upregulates p38 mitogen activated protein kinases (MAPK) resulting in weight loss, 
muscle loss and reductions in mitochondrial content160. Other common chemotherapy drugs, 
such as CPT-11 or Adriamycin promote tissue injury, either through increased production of 
inflammatory factors179 or reactive oxygen species (ROS)180.     
 Better understanding of the mechanisms underlying chemotherapy-induced cachexia may 
present possible regimens to increase the efficacy of cancer treatment today. Prior to treatment, 
patients with greater accumulation of muscle mass may be presented with the opportunity for 
generally more aggressive chemotherapeutic treatment regimens. This opportunity may be lost in 
patients who have begun to undergo severe muscle wasting or who have faced long term 
chemotherapy treatment. Therefore, patients with lower levels of muscle mass face the risk of 
drug toxicity, in accordance with decreased severity of treatment and chance of disease-free 
survival181, 182.            
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Chapter Two: Literature Review 
2.1 Skeletal Muscle and Health 
 Skeletal muscle contributes to approximately 40% of total body weight1 and is a major 
contributor to energy and protein metabolism. The health importance of skeletal muscle stems 
from its ability to provide support for locomotion, regulate glucose homeostasis2 and provide a 
site for fatty acid metabolism and glycogen synthesis3. Skeletal muscle mass is associated with 
overall risk of mortality4 and loss of skeletal muscle can lead to or worsen chronic, metabolic 
and muscle wasting associated diseases. Thus, therapeutic interventions that aim to attenuate 
skeletal muscle loss in all populations is of great interest today.    
2.1.1 Factors regulating skeletal muscle anabolism 
 The maintenance of skeletal muscle is dependent on a balance of two antagonizing 
processes, muscle protein synthesis and muscle protein breakdown. The balance between these 
two processes, often termed protein turnover is a major regulator of skeletal muscle mass. When 
protein turnover reaches a positive balance, increases in muscle protein synthesis will lead to 
skeletal muscle anabolism. Skeletal muscle anabolism is highly responsive to multiple stimuli: 
nutrition, resistance exercise and anabolic hormones.  
2.1.1.1 Nutrition and resistance exercise 
 Macronutrient ingestion, specifically protein, remains to be one of the most well-known 
anabolic regulators of skeletal muscle. Sedentary individuals require 0.8g of protein, per 
kg/BW/day according to current recommendations5. Although this recommendation is the 
standard in order to satisfy daily requirements, factors such as age, health and physical activity 
may result in the need for increased protein intake. Due to daily protein recommendations, past 
studies have investigated the effect of protein on stimulating muscle protein synthesis. Dietary 
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protein ingestion (specifically amino acids (AA)) have been shown to elicit increases in muscle 
protein synthesis6, 7. Despite an AA induced increase in muscle protein synthesis, overall protein 
turnover may remain unchanged due to matched increases in muscle protein breakdown. 
Therefore, in order to elicit muscle hypertrophy, resistance exercise is often the method of 
choice. Past evidence has shown that resistance exercise stimulates muscle protein synthesis in 
all populations8, 9, 10. In fact, resistance exercise in combination with post-exercise protein 
supplementation, elicits robust increases in muscle protein synthesis5, 7, 11, 12, 13, 14, 15, 16. In fact, 
past reports have found that bolus protein ingestions of ~20g optimally stimulates muscle protein 
synthesis following resistance exercise11.  
2.1.1.2 Anabolic hormones 
 Insulin is a potent anabolic stimulus within skeletal muscle. Although insulin may not 
directly stimulate muscle protein synthesis17, this hormone plays a pivotal role in multiple 
intermediary processes. Upon being released from the pancreas in response to hyperglycemia, 
insulin mediates the uptake of glucose into skeletal muscle. Glucose can then be used for skeletal 
muscle contraction, stored as glycogen or serve as primary fuel for many metabolic processes, 
such as protein synthesis. Insulin can also regulate the uptake of other important metabolites into 
skeletal muscle. As mentioned before, high concentrations of AA in skeletal muscle can elicit 
increases in muscle protein synthesis6, 7. Insulin has been shown to enhance muscle protein 
synthesis through the uptake of AA into skeletal muscle, but only when AA are highly 
concentrated in the plasma18. Insulin may also have an anabolic effect on skeletal muscle through 
the inhibition of proteolysis19, 20.        
 Testosterone is an anabolic hormone produced primarily within the gonads of both male 
and female sexes. This anabolic hormone increases tissue and muscle growth, as well as protein 
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synthesis. In normal male subjects, 12-week supplementation with testosterone enanthate, an 
anabolic steroid medication, led to increases in both muscle protein synthesis and muscle mass21. 
While in elderly subjects, 6-months of testosterone treatment prevented the loss of lower limb 
muscle strength22. Testosterone replacement has also been found to enhance skeletal muscle 
mass and protein synthesis in hypogonadal men23.  
 Growth hormone (GH), secreted by the pituitary gland functions as a crucial regulator of 
growth and human development. Individual’s deficient in GH exhibit decreased muscle mass, 
strength and increased body fat24. In addition, GH can have anti-insulin effects as it decreases the 
ability of insulin to increase glucose uptake in peripheral tissues such as adipose tissue 263. GH 
also functions to stimulate the production of insulin-like growth factor 1 (IGF1)25. Similarly to 
insulin, IGF1 once synthesized and activated begins a cascade of events leading to the eventual 
phosphorylation on Thr308 of protein kinase B (AKT) 26.  
2.1.2 Mechanisms of skeletal muscle anabolism 
 In order to enhance an anabolic state within skeletal muscle, insulin, growth hormone and 
testosterone must signal through specific mechanisms to augment muscle protein synthesis. 
Understanding these mechanisms are important as signalling through these pathways have 
implications in growth and maintenance of skeletal muscle over time. Skeletal muscle anabolism 
is controlled by signaling through IGF1-AKT, Mechanistic (mammalian) Target of Rapamycin 
Complex 1 (mTORC1) and Bone Morphogenetic Protein (BMP).   
2.1.2.1 IGF1-AKT          
 The IGF1-AKT signalling pathway in conjunction with multiple intracellular components 
plays a pivotal role in skeletal muscle growth. Binding of IGF1 to its cognate IGF1 receptor 
activates insulin receptor substrate (IRS) leading to the activation of the phosphatidylinositol 3-
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kinase (PI3K) family. Once activated, the PI3K family generates phosphatidylinositol-3, 4, 5-
trisphosphate (PIP3). PIP3 signals through phosphoinositide-dependent kinase 1 (PDK1) 
allowing for the subsequent activation of AKT30. Once activated, AKT mediates its effect on 
skeletal muscle anabolism through multiple mechanisms, one being the inhibition of protein 
degradation. Among others, forkhead box O (FOXO) transcription factors stimulate the 
production of MAFbx and MURF1, two E3 ligases known to induce muscle atrophy within 
skeletal muscle27. Once phosphorylated on Thr308, AKT inhibits protein degradation through the 
phosphorylation and resulting suppression of FOXO transcription factors28.    
 Aside from inhibiting protein degradation, the IGF1-AKT signaling pathway can 
stimulate skeletal muscle anabolism through its effect on glycogen synthase kinase β (GSK3β). 
GSK3β inhibits protein synthesis via its negative effect on eukaryotic translation initiation factor 
2 subunit B (eIF2B). Once activated, AKT phosphorylates GSK3β on Ser21, relieving the 
inhibitory effect of GSK3β on eIF2B29, leading to translation initiation and thus, protein 
synthesis. The IGF1-AKT pathway also augments its effect on the stimulation of skeletal muscle 
anabolism through its activation of mechanistic target of rapamycin complex 1(mTORC1).  
2.1.2.2 mTORC1           
 mTORC1 is a signal integrating hub that plays one of the most important roles in 
regulating cellular function and skeletal muscle anabolism. Through an indirect mechanism, the 
IGF1-AKT pathway provides upstream activation of mTORC1. Together, Tuberous Sclerosis 
Complex 2 (TSC2) and Tuberous Sclerosis Complex 1 (TSC1) form a complex that inhibits 
mTORC1’s activity31. Phosphorylation of the TSC2 complex by AKT at S939 and T1462 
relieves the inhibitory effect on mTORC1 leading to an increase in mTORC1’s kinase activity32, 
33. Activated mTORC1 leads to the phosphorylation of p70 ribosomal S6 Kinase 1 (S6K1). Upon 
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phosphorylation on Thr389 by mTORC1, S6K1 phosphorylates multiple downstream substrates 
such as ribosomal protein S6 (S6), eukaryotic translation initiation factor 4B (eIF4B), eukaryotic 
translation elongation factor 2 kinase (eEF2K) and programmed cell death 4 (PDCD4) resulting 
in muscle protein synthesis34, 240. In addition, mTORC1 can also phosphorylate eukaryotic 
translation initiation factor 4E-binding protein 1 (4EBP1) on several residues, leading to the 
dissociation of 4EBP1 from eIF4E. This process allows for eIF4E to upregulate initiation and 
translation machinery34, 35 ultimately leading to protein synthesis.  
 mTORC1 can also be activated directly by high concentrations of AA, specifically 
leucine. Research from past studies has shown that mTORC1 mediates the AA induced increase 
in muscle protein synthesis36. Once activated by AA, mTORC1 phosphorylates main 
downstream targets S6K1 and 4EBP1, leading to muscle protein synthesis within skeletal 
muscle. Perhaps a consequence of low dietary protein, dampened mTORC1 signalling results in 
decreased gene transcription37, cellular growth and muscle protein synthesis.  
2.1.2.3 BMP-Smad pathway 
 Bone morphogenetic proteins (BMPs) are a small group of growth factors primarily 
functioning in the formation, repair and maintenance of bone. More recently, BMPs has been 
investigated and established as positive regulators of skeletal muscle anabolism. Signalling 
through BMPs leads to the phosphorylation of downstream Smad proteins (Smad1/5/8)38 and the 
formation of a Smad4 transcriptional complex. This newly formed transcription complex then 
travels to the nucleus39 and increases the transcription of genes involved in the 
IGF1/AKT/mTORC1 pathway41.         
 Dependent on formation of the Smad4 transcriptional complex, activation of the BMP-
Smad4 pathway has been shown to regulate muscle growth and inhibit muscle atrophy in 
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innervated muscle fibers40. Part of this effect comes through the BMP-Smad4 pathway operating 
counter to a common catabolic pathway within skeletal muscle, the Myostatin/Activin pathway. 
In opposition to the formation of the Smad4 transcriptional complex, the Myostatin/Activin 
pathway reduces stem cell differentiation and induces fibre atrophy by activating transcription 
factors Smad 2 or 3267, 268. In addition, the Myostatin/Activin pathway increases muscle atrophy 
through upregulation of MAFbx and MuRF1178 and this effect is exacerbated when BMP-Smad4 
signalling is lost40. This shows that the effect of the BMP-Smad4 pathway on skeletal muscle 
hypertrophy is partly driven by outweighing signals through the Myostatin/Activin pathway. 
Other studies have also investigated the mechanism of BMP-Smad4 signaling in the promotion 
of muscle fiber hypertrophy. A novel study in 2013 found that BMP-Smad4 signaling increased 
the transcription of IGF isoforms and phosphorylation of AKTS473, mTORS2448, S6S235/236 and 
4EBP1T37/46. Interestingly, this effect of BMP-Smad4 on muscle fiber hypertrophy was 
dependent on mTORC1, as rapamycin (an mTORC1 inhibitor) completely abolished this 
effect41. This same study also elucidated that in a model of denervation-induced muscle atrophy, 
BMP-Smad4 signaling both limited muscle wasting and maintained muscle mass over time41.  
2.1.3 Factors regulating skeletal muscle catabolism 
 As mentioned before, protein turnover is a major regulator of skeletal muscle mass. 
Therefore when protein turnover reaches a negative balance, increases in muscle protein 
breakdown will lead to skeletal muscle catabolism. Aging , muscle disuse and poor nutritional 
habits are major factors that can regulate skeletal muscle catabolism and lead to muscle atrophy 
and poor muscle mass maintenance overtime. The multitude of other factors that cause 
progression of skeletal muscle catabolism will be covered under cachexia. 
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2.1.3.1 Aging           
 Aging is associated with a progressive loss of both muscle mass and function. This age 
associated condition, more commonly known as sarcopenia, causes ~1-2% drop in muscle mass 
per year in individuals past the age of 50. Sarcopenia can bring about profound consequences in 
elderly individuals related to negative health outcomes such as loss of functional ability and 
frailty42. Sarcopenia is a multi-dimensional condition caused by multiple environmental, 
physiological and metabolic changes.       
 Sarcopenia can be associated with decreased physical activity in the elderly. In both men 
and women aged 60-80 years of age, reductions in physical activity levels and functional fitness 
is associated with the aging process43. In addition, decreases in protein intake and total caloric 
requirements are important contributors to sarcopenia in older adults44. The effects of sarcopenia 
can be reduced by the ingestion of dietary proteins above current recommendations45.   
 The reduced muscle mass in the elderly is mainly attributed to decreases in type II muscle 
fiber size and quadriceps cross sectional area (CSA) compared to young individuals46. 
Additionally, declines in elderly motor neuron activity47, exercise capacity48, mitochondrial 
content/activity48 and hormones necessary for muscle mass maintenance49 contribute to 
sarcopenia.  
2.1.3.2 Muscle disuse          
 Overtime, muscle disuse can lead to rapid and detrimental atrophy within skeletal muscle. 
Muscle disuse atrophy is associated with health complications such as functional decline in 
physical working capacity, metabolic disorders and increased mortality risk4. Muscle disuse 
atrophy is often driven by either acute or chronic immobilization periods. A study in 2013 found 
that a 14-week immobilization period in young males led to reductions in quadriceps fiber 
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strength and CSA50. This reduction in fiber size and muscle mass can possibly be accounted for 
by a suppression or decline in the rate of muscle protein synthesis51. In addition, hindlimb 
immobilization found that muscle protein breakdown is also enhanced during muscle disuse 
atrophy52, but these findings in humans are not yet well defined.  
2.2 Cachexia           
 Associated with exacerbated weight loss and as a sign of forth-coming death, cachexia 
was first described by Hippocrates during the classical era53. Cachexia is a complex muscle or 
body wasting syndrome characterized by whole-body metabolic and physical abnormalities. An 
estimate in 2010 reported that approximately nine million people diagnosed with a chronic 
disease are affected by cachexia68. Metabolically, this syndrome is associated with loss of 
appetite, fatigue, aggravated skeletal muscle catabolism, increases in energy expenditure, large-
scale systemic inflammation and negative protein/energy balance54. The physical abnormalities 
of this syndrome include uncontrollable weight loss and is associated with detrimental decreases 
in fat mass, muscle mass and muscle function55. In order to be characterized as having cachexia, 
an individual needs to have lost more than 5% of their total body weight over 12 months, while 
being diagnosed with a chronic condition56. Although chronic conditions such as congestive 
heart failure and chronic renal disease positively correlate with cachexia progression, cancer is 
the dominant chronic disease associated in the development of cachexia.  With no effective or 
accepted treatments today, cachexia plays a massive burden on today’s society leading to 
reductions in quality of life (QOL) and severe complications.   
2.2.1 Quality of life          
 In cancer cachexia, persistent loss of body weight is associated with deteriorating QOL 
and likely shortens survival time in patients67. A study by Fearon et al in 2006 investigated three 
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distinctive factors related to functional status and prognosis: weight loss, reduced food intake and 
systemic inflammation. Findings from their study reported that cancer cachectic patients are 
more likely to score lower on these three measures when compared to their weight stable 
counterparts69. In association, scoring lower on quality of life measures is accompanied by 
decreases in physical activity and exercise tolerance70. Other studies have investigated the 
prevalence of depression in cancer cachexia. These reports have found that there is a higher 
prevalence of depression in cancer cachectic patients compared to the general population, but 
this clinical depression is often overlooked.71, 72. Lastly, cachexia-induced weight loss also 
affects body image. Studies have found that the significant weight loss in cachectic patients leads 
to decreases in both self-identity and self-esteem73. These issues potentiate cachectic patients to 
both self-alienate and socially isolate themselves from personal contact with others74. From this, 
cachexia can affect QOL through complications such as weight loss, reduced appetite, fatigue 
and treatment outcomes.   
2.2.1.1 Weight Loss         
 Within cachexia, significant body weight loss appears to be the most prevalent and 
detrimental complication of this syndrome. A study by Ross et al in 2004 investigated the 
probability of survival in small cell lung cancer patients undergoing chemotherapy treatment. 
They found that patients with reductions in lean body mass and its associated weight loss, had 
significantly decreased probability of survival compared to those patients with no weight loss59. 
Although the previous studies have looked at lean body mass, other studies have found that 
cachectic weight loss is not dependent on adipose tissue wasting, as obese patients with cachexia 
still exhibit large reductions in muscle weight57, 58. From this, cachexia associated weight loss 
can be attributed mainly to adverse reductions in lean body mass, specifically skeletal muscle. 
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With the health importance of skeletal muscle mentioned earlier, it is clear why weight loss 
within cachexia is major problematic complication of this syndrome. The loss of body weight 
experienced by cachectic patients can coincide with other complications including reductions in 
food intake, decreased appetite, increased fatigued and decreased physical activity.  
2.2.1.2 Reduced Appetite         
 In normal individuals, eating a healthy well-balanced diet while satisfying all the daily 
nutrient recommendations leads to the maintenance of weight. As seen in some conditions such 
as anorexia, reductions in food intake and therefore energy consumption leads to detrimental 
weight loss. In cachectic patients, symptoms of both early satiety and decreased appetite are of 
high prevalence60, but are often overlooked61. Although it can be thought that the weight loss 
experienced in cachexia is in part due to reductions in food intake and energy consumption, this 
is not the case. Multiple past reports have found that in cancer cachectic patients, dietary 
counselling62, oral nutritional support63 and dietary treatments64 did improve caloric intake, but 
had no significant effect on increasing body weight. Therefore, malnutrition is not a major 
determinant in the development of cachexia as improvements in nutrient and caloric intake do 
not rescue the adverse weight loss. Although cachexia is not due to malnourishment, 
complications such as early satiety and decreased appetite experienced by patients can lead to 
poor eating behaviours and consumption of nutrients below normal requirements. Therefore, 
these unfavourable changes in eating habits can generate a potential negative protein balance 
leading to muscle protein breakdown, further contributing to weight loss.   
2.2.1.3 Fatigue          
 A third well-known complication experienced by cachectic patients is severe weakness 
and fatigue. Approximately 70-100% of all cancer patients with cachexia experience fatigue 
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throughout the course of their disease65. With fatigue, cachectic patients often experience 
declines in the levels of physical activity due to decreased energy levels. Therefore, cachectic 
patients may avoid being physically active in order to conserve energy levels. Unfortunately, 
immobilization due to constant feelings of fatigue potentially lead to deconditioning and the 
worsening of exercise tolerance66. With this, strategies attempting to reduce fatigue and increase 
physical activity in cachectic patients are of great value. Regimens to increase physical activity 
and lessen feelings of fatigue include walking programmes, exercise sessions, reductions in 
stress levels and psychosocial support65. The inability to rescue long term fatigue in cachectic 
patients can lead to immobilization and muscle disuse contributing further to weight and muscle 
loss that is already aggravated in this condition due to other complications.  
2.2.1.4 Treatment outcomes         
 The possibility of having successful treatment of any chronic condition represents one of 
the most favourable ways to increase quality of life in patients. Unfortunately, cachexia can 
negatively impact treatment outcomes in a spectrum of different chronic diseases. For example, 
in cancer where chemotherapy is the most common treatment, cachexia-induced weight loss 
leads to decreased treatment doses and increased likelihood of drug toxicity200. In contrast, 
weight stable cancer patients respond better to cancer therapy, resulting in a greater chance of 
survival following treatment201. In patients requiring surgical treatment, cachexia increases 
surgical risk factors associated with post-operative complications, surgical complications and 
longer hospital stays202, 203. In addition, due to the array of metabolic disruptions and factors 
leading to cachexia progression, it is unlikely that a single treatment modality would provide 
successful treatment for cachectic patients204.        
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2.3 Factors regulating cachexia         
 Similar to the factors regulating skeletal muscle catabolism, factors leading to cachexia 
progression potentiate a negative balance within protein turnover. A negative protein balance can 
lead to extreme proteolysis matched with debilitating muscle atrophy. Chronic disease, 
inflammation, reactive oxygen species (ROS) and chemotherapy are all factors regulating 
cachexia development and progression.  
2.3.1 Chronic disease          
 Chronic disease represents one of the major determinants in the development of cachexia 
today. Individuals diagnosed with chronic diseases such as chronic heart failure (CHF), chronic 
kidney disease (CKD) and cancer will face one or more of the symptoms of cachexia throughout 
the duration of their disease. Cachexia affects a large majority of the patients diagnosed with 
these diseases and in the United States, more than 5 million people are affected by this muscle 
wasting syndrome97. From this, cachexia is a significant public health issue and interventions 
that attenuate the onset or progression of cachexia could provide vast therapeutic benefits. 
2.3.1.1 Chronic Heart Failure         
 CHF is a well-known cardiovascular disease leading to higher rates of morbidity and 
mortality in elderly populations98. Cardiovascular diseases effects ~2% of the population100 and 
the likelihood of developing CHF doubles after the age of 55. Majority of the individuals 
diagnosed with CHF are burdened by symptoms including shortness of breath, tiredness and 
irregular heartbeat. Unfortunately, treatment and therapeutic options for this disease are minimal 
and revolve around palliative care and pharmacological support241.    
 Approximately 5-15% of all elderly patients diagnosed with CHF experience cardiac 
cachexia, characterized by loss of muscle mass and function compared to healthy elderly 
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people99. CHF patients may also experience loss of fat tissue and bone density, all of which 
contribute to reduced body weight. Studies have also found that CHF patients with cachexia have 
a very poor prognosis leading to an impact on quality of life101. From a pathophysiology 
viewpoint, CHF patients are observed to have increased plasma levels of cortisol and 
inflammatory cytokines, specifically TNF-α, that aggravate muscle wasting102. Further, a study 
in 2016, investigated the effect of cardiac cachexia on heart health in CHF patients. Cardiac 
cachexia was associated with higher rates of atrial fibrillation, as well as impairments in 
posterior wall thickness and left ventricular ejection fraction103. These negative effects induced 
by cardiac cachexia potentiate higher blood pressure, an important complication and contributor 
to mortality rates in CHF patients.         
2.3.1.2 Chronic Kidney Disease         
 CKD effects approximately 850 million people worldwide and contributes to an increase 
in morbidity and mortality of elderly individuals104. CKD is a common term used to describe an 
illness characterized by a loss of kidney function. Although CKD is often asymptomatic, this 
disease is most often accompanied or diagnosed with other comorbidities such as diabetes or 
cardiovascular disease105. Diagnosis of CKD may also expose individuals to an increased 
likelihood of acute kidney injury, further contributing to greater morbidity and mortality risk. 
Novel nutritional based therapeutic interventions are on the rise, but early detection may be 
important in reducing future risk.         
 With 18-75% of patients with CKD showing evidence of muscle wasting, cachexia is 
relatively prevalent in this disease106. The large range of cachexia incidences is due to the 
different comorbidities that can be present in CKD. Multiple factors and signalling molecules 
have been reported in the pathogenesis of cachexia in CKD patients107-111. Although malnutrition 
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does not solely induce wasting, studies have investigated the link between appetite controlling 
hormones and the prevalence of cachexia in CKD. One study found that in CKD patient’s leptin 
levels were severely increased in the blood, leading to hyperleptinemia and cachexia107, 108. Other 
studies have reported that ghrelin, a hunger hormone, is decreased in CKD patients leading to 
early satiety and decreased appetite109. Aside from appetite control, studies have also 
investigated the presence of inflammatory cytokines in CKD. These studies find that compared 
to healthy patients, inflammatory cytokine levels are much higher in kidney disease patients108, 
110. Lastly, upregulation of proteolytic mechanisms, specifically the caspase-3 and the ubiquitin 
proteasome pathway are also implicated in the progression of cachexia in CKD111. 
2.3.1.3 Cancer            
 Every year, approximately ten million people or more are diagnosed with cancer around 
the world112. This makes cancer the second leading cause of death worldwide behind 
cardiovascular disease. Contributing to a larger mortality risk, cancer of the lung, female breast, 
bowel and prostate are the most common diagnosed. Cancer can be defined as chronic mutated 
and uncontrollable cell growth within a given tissue. As symptoms often depend on the type of 
cancer diagnosis, common signs may include unforeseen or persistent lumps, bloody urine, 
hoarseness, difficulty swallowing and unexpected, but extreme weight loss242. With the potential 
for negative treatment outcomes, cancer may soon be the biggest health burden in today’s 
society, especially for elderly populations112.     
 Cachexia occurs in 80% of all cancers113, making cancer the leader in disease-associated 
cachexia. Cancer of the pancreas, oesophagus, stomach, lung and liver account for the majority 
of cancer deaths worldwide114, and it comes as no surprise that cachexia is largely associated 
with each of these cancer types. The cachectic weight loss although mainly comes from skeletal 
17 
 
muscle wasting, adipose tissue, specifically brown adipose tissue is seen to have an important 
role in cachexia122. In addition to having a severe negative impact on QOL, cancer patients with 
cachexia respond poorly to chemotherapy treatment compared to weight-stable patients115, 116. 
Pathophysiology of cancer cachexia partly revolves around disruptions and imbalances in protein 
metabolism. In cancer cachexia, the rate of catabolism significantly outweighs the rate of 
anabolism in skeletal muscle leading to net protein breakdown and muscle atrophy118, 119. 
Increases in energy expenditure and consequently resting energy expenditure is also implicated 
as contributing to the wasting process, especially in pancreatic and lung cancer120, 121. Lastly, 
during cancer progression, there is undoubtedly a significant increase in the levels of pro-
inflammatory cytokines tumour necrosis factor-alpha (TNF-α), interleukin 6 (IL-6) and 
interleukin 1 (IL-1)117.  
2.3.2 Inflammation          
 Systemic inflammation indicated by the production of pro-inflammatory cytokines is 
arguably the biggest contributor to the regulation of cachexia117. Cachectic patients exhibit 
elevated levels of TNF-α, IL-6 and IL-1 and these pro-inflammatory cytokines are all positively 
correlated with causing cachexia-like effects76. Although these three cytokines may have 
differing mechanisms of action, TNF-α, IL-1 and IL-6 can all readily cross the blood brain 
barrier and affect appetite77.         
 The pro-inflammatory cytokine TNF-α is one of the most well-known and studied 
mediators of cachexia. A study in 2005 by Li et al investigated the effect of TNF-α on the 
expression of atrogin1, a gene responsible for skeletal muscle atrophy. The study found that in 
vitro, TNF-α actively works via the expression of atrogin1 to induce myotube atrophy78. Other in 
vitro studies have shown that TNF-α is implicated in the production79 and signalling80 of reactive 
18 
 
oxygen species (ROS). In vivo, studies have found that tumour-bearing mice result in increased 
levels of TNF-α and this cytokine is responsible for muscle protein breakdown in skeletal 
muscle81. Interestingly, although TNF-α leads to increased proteolysis and decreased protein 
synthesis76, inhibition of this cytokine does not stop or slow cachexia progression82.  
 Aside from TNF-α’s effect on cachexia, TNF-α also augments the formation of another 
pro-inflammatory cytokine, IL-176. Over time, IL-1 has been implicated in causing anorexic 
states in cachectic patients. An in vivo study by Dunn AJ in 1988 found that intraperitoneal 
injections of IL-1 increased tryptophan levels throughout the brain83. The IL-1 induced increase 
in tryptophan levels leads to subsequent increase in serotonin levels. From this, increased 
serotonin levels have been shown to both suppress hunger and limit appetite84. It is through this 
indirect mechanism of hunger and appetite suppression that IL-1 can regulate cachexia. Aside 
from this mechanism, IL-1 can also induce the production of IL-6.     
 Although IL-6 is an anti-inflammatory myokine, IL-6 is also a well-known mediator of 
cachexia. A study by Strassmann et al in 1992 found that in tumour-bearing mice, cachexia 
progression was associated with increased levels of IL-6. In tandem, this same study also 
elucidated that a monoclonal antibody to IL-6 reduced cachexia progression in vivo85. In 
cachectic patients, levels of IL-6 appear to be lower in weight-stable patients compared to their 
cachectic counterparts76. While in human trials of cancer patients, IL-6 is associated with weight 
loss in some patients86, but not all87.          
 It is clear from the literature that pro-inflammatory cytokines have diverse systemic 
effects and mechanisms that regulate cachexia. It is also worth addressing that the relationship 
between inflammation and cachexia is a complex interplay of multiple factors and mechanism 
that regulate cachexia as a whole. Therefore, further studies elucidating the effects of multiple 
19 
 
pro-inflammatory cytokines on cachexia development and progression should be of great interest 
today.  
 2.3.3 Reactive oxygen species         
 Reactive oxygen species (ROS) are highly reactive oxygen-derived molecules normally 
produced as by-products from cellular metabolism or mitochondrial activity. The most common 
types of ROS include superoxide (O2-) and hydrogen peroxide (H2O2). In a healthy cellular 
environment, ROS helps to maintain normal physiological functioning mainly through its 
interaction with cysteine residues on protein89. However, due to complications such as 
environmental stress, metabolic alterations and disease, increases in ROS levels can lead to 
oxidative damage90. Previous studies have reported that uncontrolled ROS levels can contribute 
to cellular impairments, skeletal muscle atrophy, macromolecule damage, DNA damage and 
pathogenesis of disease91. Fortunately, the human body has well-structured antioxidant defences 
that help control against extreme levels of oxidative stress. Common antioxidant enzymes 
include superoxide dismutase (SOD), catalase and glutathione peroxidase (GPx). From this, 
imbalances through either increases in ROS or decreases in antioxidant enzyme activity will 
perpetuate oxidative damage90, 92.          
 Overtime, elevated oxidative damage has been implicated in the progression and 
development of cachexia. Both in vitro and in vivo studies have reported the association between 
ROS and cachectic states. A study by Russell et al in 2007 found that increases in ROS 
formation induced by proteolysis-inducing factor and angiotensin II led to total protein 
degradation in murine myotubes93. Similarly, a study by Barreiro et al in 2005 investigated levels 
of protein carbonylation in tumour-bearing mice. The study found that in the muscles of tumour-
bearing mice, protein carbonylation was significantly greater compared to control muscles, 
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signifying increases in oxidative damage96. Other studies have reported decreases in antioxidant 
enzyme activity in cachectic states. A study by Sullivan-Gunn et al in 2011 investigated the 
enzyme activity of SOD1 and SOD2 in the muscle of mice with cancer cachexia. Cancer 
cachectic mice were associated with decreases in SOD1 and SOD2 enzyme activity matched 
with increases in O2 levels
94. Likewise, past reports have also shown decreases in the levels of 
antioxidant enzymes catalase95 and GPx94 in cachexia studies. Taken together, these studies 
suggest that cancer cachectic patients not only experience elevated ROS levels, but also 
reductions in the antioxidant protective properties normally guarding against oxidative damage. 
2.3.4 Chemotherapy Treatment         
 Chemotherapy is one of the most common cancer treatments today. With cancer being 
the leader in disease-associated cachexia, it is important to discuss and understand how common 
chemotherapy drugs can regulate cachexia. Broadly, chemotherapy acts through the induction of 
death in tumour cells123, by damaging DNA necessary for cell division. Unfortunately, due to the 
complexity of cancer and the fact that anticancer strategies, specifically chemotherapy are not 
specific to the tumour itself124, many other bodily processes are affected. For instance, 
administration of single chemotherapy drugs in cancer patients often leads to drug toxicity and 
resistance, resulting in treatment failure and often death125. From this, resistance to cancer 
chemotherapy is a major problem in cancer therapy. To account for this problematic feature, 
cancer therapy has turned to combining multiple chemotherapy drugs, administered as a cocktail. 
Combining multiple chemotherapy drugs have been shown to not only reduce drug toxicity and 
resistance, but also reduce side effects as separate drugs can be administered at lower 
concentrations126. In addition, combining multiple chemotherapy drugs can lead to increases in 
the bioavailability of drugs127, leading to the enhanced effect of these drugs on killing cancer 
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cells. Among others, common treatment regimens that utilize combinations of chemotherapeutic 
drugs include folfiri, a combination of Leucovorin (Leu), 5-Fluourouracil (5-Flu) and irinotecan 
and folfox, a combination of Leu, 5-Flu and oxaliplatin. Nonetheless, chemotherapy treatment, 
used in combination or not, is still associated with side effects, including nausea, vomiting, 
appetite changes, constipation and hair loss. Of all these effects, none match the detrimental 
skeletal muscle wasting and atrophy that can ensue through chemotherapy treatment. 
2.3.4.1 Cisplatin           
 Cis-diamminedichloroplatinum (II), better known as cisplatin, is a platinum-containing 
compound present as a yellow crystalline powder at room temperature. Dating back to cisplatin’s 
first scientific investigation in the 1960s by Rosenberg128, the focus on using platinum containing 
compounds as anti-cancer agents has increased drastically. In 1978, cisplatin became the first 
platinum compound to gain FDA approval for the use as cancer treatment129. Since then, 
cisplatin has become best known for being a potent chemotherapeutic drug used most commonly 
in treatment of testicular, ovarian, head, lung and neck cancers.      
 It is relatively clear that the main mechanism of cisplatin’s anti-cancer effect comes 
primarily through the targeting of deoxyribonucleic acid (DNA). Once cisplatin enters a cell, 
often through passive permeation130, previous reports have linked cisplatin’s cytotoxic action 
with the induction of intrastrand DNA adducts131, 132. Often times, DNA adducts not removed 
from the cellular environment could give rise to problematic mutations. Therefore, in response to 
DNA adducts, p53 and mitogen-activated protein kinase (MAPK) signalling pathways become 
activated, inducing cellular apoptosis. Specifically, cisplatin has been shown to activate MAPK 
c-jun terminal kinase (JNK), leading to the transcription of fas ligand (FasL) and the induction of 
cisplatin-mediated apoptosis264. In addition, p53 can also have an effect on cell cycle 
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checkpoints, causing arrest in the G, G1 and S phases of the cell cycle132. This effect is 
particularly important as cisplatin, a chemotherapeutic drug should have positive effects on 
reducing the abnormal and uncontrolled cell growth present in cancer cells.    
 Unfortunately, cisplatin has at least two problematic side effects. Under cisplatin 
administration, patients can experience drug toxicity leading to ineffective treatment and 
negative health outcomes. Normally, patients receive cisplatin treatment every 3-4 weeks at a 
dose of about 50-100mg/m2 intravenously. Dosage can depend on multiple factors: renal 
function, age, muscle mass, cancer type and combination with other antineoplastic agents133. 
Inadvertently, cisplatin overdose leading to toxicity can also become apparent in patients when 
dosage amounts reach upwards to 480mg/m2134. Symptoms of cisplatin toxicity may include 
nausea, vomiting, nephrotoxic associated renal insufficiency and myelosuppression133. 
Management of cisplatin toxicity is therefore critical in order to support proper health outcomes 
in patients. Such management includes antiemetic support, aggressive hydration, red blood cell 
transfusions, supportive therapies and avoidance of other drugs that may bring about similar 
symptoms133. Aside from drug toxicity, patients receiving cisplatin treatment overtime may also 
face unforeseen resistance to this anti-cancer agent. Cisplatin resistance is associated with a 
myriad of cellular changes that reverse the mechanism of cisplatin’s effect. Constant exposure of 
cisplatin leads to the development of a phenotypic self-defence system that allows cells to escape 
the cytotoxicity of cisplatin. These phenotypic changes include decreases in platinum derived 
DNA-adducts, as well as changes in gene expression associated with apoptosis, DNA-damage 
repair, mitochondria metabolism and the cell cycle135, 136, 137. Of all the changes that occur, 
reductions in the accumulation of cisplatin in cells presents a defining feature of cisplatin 
resistance. This is evident in human cisplatin resistant cells, where significant reductions in 
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platinum-induced DNA-adducts are found138. In addition, the reduced accumulation and 
resistance of cisplatin, may also be a factor of impaired uptake or increased efflux of platinum 
compounds within cells139, 140, 141.         
 With regards to the effect of cisplatin on inducing cachexia, one of the most common side 
effects or symptoms of cisplatin treatment is muscle fatigue. A study by Sakai et al in 2014 
investigated the effect of 3mg/kg of cisplatin on muscle atrophy in mice over four days. 
Compared to vehicle, cisplatin treated mice exhibited decreased body weight associated with 
reductions in quadriceps muscle mass, coinciding with dramatic increases in Muscle atrophy F-
Box (MAFbx) and Muscle RING Finger-1 (MuRF1)158. Cisplatin has also been shown to induce 
the expression of nuclear factor kappa-light-chain-enhancer of activated B cells (Nf-ΚB)159, 
pointing to a likely mechanism of protein ubiquination and degradation in muscle. Due to side 
effects of drug resistance, toxicity and muscle fatigue, cisplatin can often be used in combination 
with a separate chemotherapy drug, 5-Flu. In combination, cisplatin and 5-Flu can effectively 
treat cancer of the head, neck, anus and esophagus. 
2.3.4.2 5-Fluourouracil         
 5-Fluourouracil (5-Flu) is a well-known analog of uracil possessing both immunological 
and anti-metabolic properties. This compound is a fluorinated pyrimidine present as a white 
crystalline powder at room temperature. Since being first synthesized in 1957 by Heidelberger et 
al142, investigations into the antineoplastic activity of 5-Flu became of great interest. Today, 5-
Flu is a well-studied chemotherapeutic drug used both singularly and in combination with other 
chemotherapy drugs. Specifically, 5-Flu is used for the treatment of colon, pancreatic, breast, 
gynecological, head and neck cancers143.   
 Similar to cisplatin, the antineoplastic activity of 5-Flu comes primarily through the 
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action of this compound on DNA. The discovery of 5-Flu came through the finding that 
hepatoma tumours from rats formed DNA from uracil at a more rapid pace than healthy tissue. 
Therefore, Heidelberger and colleagues designed 5-Flu to differ from uracil by substituting 
uracil’s hydrogen at the carbon-5 position with a fluorine atom142, 144. Once incorporated into the 
cell, either through non-facilitated diffusion or facilitated nucleobase transport145, 5-Flu 
undergoes a myriad of changes as 5-Flu by itself is inactive. Intracellularly, 5-Flu is converted 
into 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), a critical nucleotide metabolite in 5-
Flu’s mechanism of action. Once formed, FdUMP inhibits thymidylate synthase, a regulatory 
enzyme that is responsible for DNA synthesis146. Due to this mechanism, TS, especially with 5-
Flu treatments becomes a critical target for cancer chemotherapy142. In addition, 5-Flu can be 
converted into 5-fluorodeoxyuridine-5'-triphosphate (FdUTP) leading to inhibition of DNA 
synthesis and function146. Additionally, 5-Flu can also be converted into 5-fluorouridine-
5'triphosphate (FUTP) leading to inhibition of RNA synthesis and mRNA translation147.  
 Again similarly to cisplatin, treatment with 5-Flu can overtime leads to an increase in 
drug resistance, drug toxicity and ultimately decreased effectiveness. On average, patients 
receive bolus 5-Flu treatment every 4 weeks at a dose of about 500mg/m2 intravenously152. 
Different dosages can depend on factors such as cancer type, dosage schedule and combinations 
with other chemotherapy drugs. Due to the fact that 5-Flu can be metabolized and excreted 
rapidly within the human body, determining toxicity can be both difficult and challenging. 
Nonetheless, the major cause of 5-Flu toxicity is due to a deficiency in Dihydropyrimidine 
dehydrogenase, the rate limiting enzyme in 5-Flu catabolism153. Deficiency of this enzyme 
occurs in about 3-5% of all patient populations155, leading to symptoms of 5-Flu toxicity such as 
lleukopenia, diarrhea, stomatitis and nausea154. In addition to drug toxicity, many past reports 
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have also found 5-Flu resistance as another problematic feature of this drug. Increases in the 
catabolic activity of enzymes responsible for breaking down FdUMP, FdUTP and FUTP may 
result in decreased accumulation of active 5-Flut144. In addition, reductions of 5-Flu 
incorporation into both DNA and RNA may lead to drug resistance148. With regards to 
thymidylate synthase specifically, 5-Flu treatment augments increases in thymidylate synthase 
protein content and protein synthesis, leading to increased requirements for 5-Flu dosages149, 150. 
Lastly, any mutation in the coding region of thymidylate synthase may affect the ability of 
FdUMP to bind and inhibit this enzyme151.         
 Interestingly, not much research has been conducted on the effects of 5-Flu by itself on 
muscle atrophy. Nonetheless, similarly to cisplatin, fatigue plays a crucial role in 5-Flu treatment 
symptomatology. In 2014, a study by Barreto et al investigated the mechanisms of Folfiri and 
Folfox, two 5-Flu combinatory cocktails on chemotherapy-induced cachexia in mice. The study 
reported that both chemotherapy regimens led to concurrent weight and lower-limb muscle loss, 
associated with upregulation of p38 mitogen activated protein kinases (MAPK) and reductions in 
mitochondrial content160. From this and the above mechanisms, it is clear that drug toxicity, drug 
resistance and even metabolism of 5-Flu can be problematic features that inhibit the effect of this 
chemotherapy drug on killing cancer cells. Specifically, one medication, leucovorin, has been 
shown to be mechanistically important to increase the effectiveness of 5-Flu. The effects of a 5-
Flu and leucovorin cocktail are outlined below.  
2.3.4.3 Leucovorin           
 Leucovorin, also known as folinic acid, is a medication that can be used to treat folate 
deficiency and also to decrease the toxicity of certain chemotherapy agents. Of all the effects, 
leucovorin is most commonly used clinically in combination with 5-Flu. When used with 5-Flu, 
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leucovorin is often administered just prior to 5-Flu’s intravenous infusion with a dose of 
20mg/m2 5 times over 4 weeks or 400mg/m2 once over 2 weeks. Intracellularly, leucovorin is 
reduced to folate 5, 10-methylenetetrahydrofolate and in this form, reduced leucovorin can bind 
and form a complex with FdUMP, a major metabolite of 5-Flu. The FdUMP-leucovorin complex 
can now better bind to thymidylate synthase, leaving this enzyme in a maximally inhibited state 
and ultimately significant reductions in DNA biosynthesis146. Interestingly, since 5-Flu is often 
metabolized and excreted from the body rapidly, the increased binding to thymidylate synthase 
allows 5-Flu to be present in the cell for longer allowing for increased effectiveness. Multiple 
past reports have also supported the efficacy of a leucovorin and 5-Flu combination. Work by 
Sotos et al, found that the cytotoxic action of 5-Flu was enhanced when used in combination 
with leucovorin156. Other studies have also supported the notion of significantly higher response 
rates with 5-Flu and leucovorin together opposed to 5-Flu alone157. It should also be noted that 
although leucovorin is not a chemotherapy drug, symptomology with this medication is still 
prevalent as leucovorin is almost always used in combinations with other chemotherapy drugs.  
2.4 Mechanisms of skeletal muscle catabolism      
 In order for a cachexia to occur, factors such as chronic disease, inflammation, reactive 
oxygen species and chemotherapy treatment must signal through specific mechanisms to elicit 
muscle protein breakdown. Skeletal muscle catabolism can occur through a shift in protein 
equilibrium, either through an increase in protein degradation or a decrease in protein synthesis. 
Unfortunately, the mechanisms associated with the pathophysiology and development of skeletal 
muscle catabolism and cachexia are often complex, multidimensional and very poorly 
understood. Understanding the complex mechanisms of cachexia development and progression 
may shed light on potential therapeutic interventions to manage cachexia-induced muscle loss. 
27 
 
2.4.1 Ubiquitin Proteasome Pathway        
 The Ubiquitin Proteasome Pathway (UPP) accounts for the vast majority of protein 
degradation in mammalian cells161. Within this pathway, the 26S proteasome, is a crucial protein 
complex necessary for degrading proteins that have been tagged for degradation161. Before the 
26S proteasome can degrade proteins, substrates must be conjugated by multiple units of 
ubiquitin by a cascade of enzymes. First, ubiquitin is activated by an activating-enzyme (E1) and 
transferred to a ubiquitin carrying molecule (E2). Next, E2 bound ubiquitin can recognize E3 
ligases and in turn, E3 ligases can bind and form ubiquitin chains on protein substrates. Two of 
the most common and studied E3 ligases have been identified to actively contribute to 
proteolysis and associated muscle loss are MAFbx/atrogin-1 and MuRF1163. Only once a protein 
has been conjugated with a chain of ubiquitin by the E3 ligases can the 26S proteasome act to 
degrade the protein substrates162.        
 Within cachexia, multiple past reports have found that the UPP is severely upregulated164, 
165, showing a pivotal role of this pathway in protein degradation. In addition, in catabolic 
models of fasting, diabetes and cancer cachexia, the upregulation of E3 ligases MAFbx and 
MuRF1 have been deemed essential for associated muscle protein loss163, 166, 167. Therefore, 
much research has attempted to identify upstream transcription factors of these E3 ligases.  
2.4.2 Autophagy           
 Autophagy is a highly regulated recycling process present in all mammalian cells. Since 
autophagy is involved in protein and cellular recycling, autophagy has been well recognized as 
vital to maintenance and survival of cells244.  There are three primary forms of autophagy: 
microautophagy, macroautophagy and chaperone mediated autophagy, all of which function to 
transport substrates to the lysosome for recycling245. The most commonly studied, 
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macroautophagy, involves the formation of a double-membraned vesicle, an autophagosome, 
which engulfs substrates and transports them to the lysosome246. Often induced by nutrient or 
energy starvation, autophagy may be a cytoprotective mechanism to maintain cellular function 
and growth. Unfortunately, dysregulated autophagic mechanisms is associated in the progression 
of human pathologies such as cancer and metabolic diseases, such as diabetes244, 247.    
 Since autophagy involves the recycling and breakdown of protein substrates, past reports 
have investigated the relationship between cachexia and autophagic mechanisms. A study in 
2016 by Aversa et al investigated the levels of autophagy markers in the skeletal muscle of 
cancer cachectic patients. In cancer cachectic patients, both beclin-1 and LC3B-II protein levels 
were significantly increased, signifying autophagy induction and autophagosome formation 
respectively248. Mitochondrial selected autophagy, also known as mitophagy, also showed a 
trend to be increased in cancer cachectic patients248. Other past reports have also found 
autophagic degradation as a significant contributor to muscle wasting in lung249 and 
esophageal250 cancer cachectic patients.     
2.4.3 Apoptosis            
 Also known as programmed cell death, apoptosis is a vital process necessary for normal 
immune system activity, as well as proper cellular homeostasis, development and turnover. Since 
apoptosis is involved in cell death, great interest is focused on how the mechanisms of apoptosis 
is regulated in skeletal muscle. Intrinsically, the process of apoptosis is initiated by DNA damage 
or cellular stress caused by factors such as hypoxia, toxins and radiation205. In turn, these stress 
stimuli augment mitochondrial permeablization, the release of cytochrome c and the formation of 
the apoptosome. The apoptosome leads to the irreversible activation of caspase 9 and caspase 3 
leading to cellular disassembly, degrading of intracellular substrates and cell death205, 206. 
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 Although homeostatic levels of apoptosis can be critical to normal cellular functioning, 
levels of apoptosis can be increased in normal aging207, muscle denervation208 and cancer 
cachexia209. Increased levels of apoptosis in muscle atrophy conditions suggest that apoptosis 
may play a role in loss of muscle mass over time. A study by Belizario et al in 2001 investigated 
the activation of caspase-induced apoptosis in tumour-bearing mice affected by cachexia. 
Compared to non-tumour-bearing mice, the study found that tumour-bearing mice had 
significantly increased caspase 1, 8, 3, 6 and 9 in the gastrocnemius muscle. In addition, 
cytochrome c was found to be released from mitochondria, providing further evidence of 
increased apoptosis in cancer cachexia-induced muscle loss209.  
2.4.4 Calcium-Calpain          
 Calpains are calcium-dependent proteases, regulated by a wide variety of factors within 
skeletal muscle. As the name implies, calpains are regulated by calcium223, as well as 
phospholipids and calpastatin224, a calpain inhibitor. The mechanisms of calpain-induced muscle 
damage is multifactorial, but the end result of protein degradation remains constant. Activation 
of the calpains is associated with sarcomeric disturbances, resulting in damaged and degradation 
of myofilaments by the 26S proteasome225. In addition, calpain activity can lead to the promotion 
of two factors involved in muscle wasting, TNF-α226 and Nf-KB227. Recent studies have also 
shown an inhibition of AKT by the calpains228, resulting in protein degradation by the 26S 
proteasome either through a suppression of mTORC1 or upregulation of FOXO proteins and 
GSK3β. Aside from an indirect effect on the 26S proteasome, past reports suggest that calpains 
may directly regulate the 26S proteasome with the calcium ionophore A23187229.   
 Due to the above mechanisms, it is relatively clear why investigating the effects of 
calpains in skeletal muscle atrophy is critical. Studies from sepsis-induced cachexia show both 
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indirect and direct evidence of calpain expression in skeletal muscle230, 231, 232, 233. In cancer 
cachexia, both calpain mRNA expression234 and proteolysis through calcium-dependent 
mechanisms235 were upregulated in tumor bearing rats. More recently, as study in 2017 by Lin et 
al investigated whether calpain inhibitors would ameliorate cachectic effects in tumour-bearing 
mice. In tumour-bearing mice, calpain activity was associated with decreased body weight, 
gastrocnemius muscle mass and increases in MuRF1 and atrogin-1 gene expression. 
Interestingly, calpain inhibitors were able to reverse the expression of atrophic genes, leading to 
improved weight and survival outcomes in tumour-bearing mice239. Calpain mechanisms have 
also been reported to play a role in other conditions such as sarcopenia236, muscle unloading237 
and chronic heart failure238.   
2.5 Signalling towards mechanisms of skeletal muscle catabolism   
 During cachexia, skeletal muscle catabolic mechanisms can be driven by the upregulation 
of transcription factors and enzymes. Associated with cachexia and muscle loss, O-type forkhead 
(FOXO), Nf-ΚB and Myostatin are three families of transcription factors that can upregulate 
MAFbx/atrogin-1 and MuRF1 expression. In addition, enzymes such as caspases (mentioned 
previously) and Unc-51 Like Autophagy Activating Kinase 1 (ULK-1) also upregulate skeletal 
muscle catabolism. 
2.5.1 O-type forkhead          
 Expressed within skeletal muscle, FOXO is a family of transcription factors made up of 
FOXO1, FOXO3a and FOXO4. Specific to skeletal muscle, past reports have found that FOXO 
transcription factors are highly expressed during atrophic conditions167, 168, 169. Once activated 
either by c-Jun N-terminal kinase (JNK) or macrophage stimulating 1 (MST1) regulators243, 
FOXO transcription factors travel to the nucleus and have the ability to activate E3 ligases 
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MAFbx and MuRF1170, 171, enhancing protein degradation through the UPP. Past reports have 
also investigated the transcriptional activity of FOXO in cachectic models. A study by Reed et al 
in 2012, investigated the regulation of gene transcription and muscle fiber atrophy by FOXO in 
two cachexia conditions, cancer and sepsis. The study found that cachexia increased the mRNA 
expression and transcriptional activity of FOXO family members. In addition, FOXO activation 
was required for cachexia-induced muscle fiber atrophy associated with increased expression of 
atrophy related genes MuRF1 and MAFbx172. These findings point to a crucial role of FOXO in 
the transcriptional upregulation of key atrophy related genes in cachectic conditions.  
2.5.2 Nf-ΚB            
  Nf-KB is a family of transcription factors involved in cell survival, inflammation and 
immunity. Normally, Nf-ΚB is bound to inhibitory protein of ΚBα (IΚBα) and stuck in the 
cytoplasm. Once phosphorylated by inhibitor of kappa light polypeptide gene enhancer in B-cells 
(IKK), IΚBα is unbound and degraded by the 26S proteasome and NF-ΚB is free to translocate 
to the nucleus173. Upon nuclear accumulation, NF-ΚB can upregulate the expression of E3 
ligases MAFbx and MuRF1174, leading to ubiquination and greater activity through the UPP. 
Unfortunately, the exact role of Nf-ΚB in cachexia and muscle wasting is poorly defined. A 
study in 2011 found that in cancer cachectic mice, NF-ΚB bound near transcription start sites of 
MAFbx, MuRF1 and caspase 3 showing the requirement NF-ΚB signaling in cancer cachexia175. 
In addition, studies have also shown that NF-ΚB transcription factors can be regulated upstream 
by the formation of ROS176. From this, a possible mechanism of cachexia through NF-ΚB is 
introduced. As mentioned previously, elevated ROS in cachexia, either through direct increases 
in ROS levels or decreased antioxidant enzyme activity, may lead to downstream activation of 
NF-ΚB, increased expression of E3 ligases, augmenting 26S proteasome activity and protein 
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degradation.  
2.5.3 Myostatin           
 Also known as growth differentiation factor 8, myostatin is a myokine part of the TGFβ 
superfamily and a known negative regulator of muscle growth. Often increased through 
glucocorticoid stimulation, myostatin inhibits activation of AKT by inhibiting IGF-1265, leading 
to the upregulation of atrophy related genes MAFbx and MuRF1 through FOXO3178. Therefore 
the mechanism of myostatin’s effect on muscle atrophy through the UPP is similar to that of 
FOXO3 and NF-KB. In vitro, myostatin has been found to have a negative effect, decreasing 
both size and numbers of myotubes178. Interestingly, systemic overexpression of myostatin 
induces body weight, muscle and fat loss in mice177, 178 comparable to the losses observed in 
cancer cachexia.  
2.5.4 ULK-1           
 Unc-51 like Autophagy Activating Kinase 1 (ULK-1) is a serine/threonine protein kinase 
necessary for autophagy signalling, as disruption of the ULK-1 complex can inhibit 
autophagy254, 255. One of the most known upstream regulators of ULK-1 is mTORC1, as amino 
acid activation of mTORC1 phosphorylates ULK-1, inhibiting ULK-1’s kinase activity256, 257. In 
contrast, activation of ULK-1 by amino acid starvation258, AMP activated protein kinase 
(AMPK)259 or glycogen synthase kinase 3260 can keep ULK-1 in the dephosphorylated state, 
ultimately activating autophagy. Related to cachexia, a previous report has shown that in tumour-
bearing mice, ULK-1 plays a crucial role in autophagy induction mediated by p38β MAPK261.  
2.6 Current treatments          
 It should first be stated that there are currently no effective or accepted treatments for 
cachexia. In addition, due to the multi-array of cachectic factors experienced by patients, it is 
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often necessary to develop forms of treatment specific to each patient. A study in 2001 suggested 
that with cancer patients, treatment of cachexia relied solely on curing the cancer itself75. With 
the option to cure cancer not always viable, multiple reports have focused on developing 
effective treatments for cachexia.        
 During the mid-1990s, studies focused on the maintenance of lean body mass by 
attempting to decrease the levels of a TNF-α, a known factor in the development of cachexia. 
Two human trials, focused on using either drugs such as pentoxifylline210 or hormones such as 
melatonin211, but both showed little efficacy in limiting cachexia-induced muscle loss. More 
recently, studies have attempted to use combinations of nutritional and pharmaceutical based 
supplements in treating cachexia. In a phase II trial by Mantovani et al, treatment included a diet 
high in polyphenols, antioxidants, polyunsaturated fatty acids mixed with celecoxib and a dose 
of medroxyprogesterone acetate pharmaceuticals. After four months, the treatment had a positive 
effect on body weight, lean body mass, appetite, fatigue and in addition, led to decreased 
inflammatory cytokine levels IL-6 and TNF-α212.      
 In addition to these nutritional combination therapies, studies have also examined the 
potential to increase skeletal muscle anabolism through testosterone therapy in cachectic 
patients. Two studies conducted within the same lab in 2013 and 2018, investigated the effect of 
adjunct testosterone compared to placebo in cachexia-related muscle loss. In 2013, the study 
found that testosterone led to greater total body mass associated with positive changes in lean 
body mass213. In 2018, with a similar study design, testosterone led to 3.2% increases in lean 
body mass, as well as positive outcomes in activity levels and quality of life. Unfortunately, both 
placebo and testosterone treated groups did not differ in overall survival214.    
 Since testosterone positively impacted lean body mass, but did not increase survival 
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outcomes, past reports have also looked at the inhibition of skeletal muscle catabolism through 
modulation of the UPP. Eicosapentaenoic acid (EPA) is a health promoting agent often 
investigated in cachectic environments due to the fact that EPA is the only known nutritional 
supplement that acts on the UPP215. Treatment with EPA has been shown to reduce inflammatory 
cytokines216, mitigate the activity of Nf-KB217 and reduce critical subunits involved in 
mechanisms of proteolysis218. In animal trials, EPA supplementation leads to increases in SOD 
activity following chemotherapy treatment219 and positively affects muscle function in tumor 
bearing mice when combined with leucine220. In addition, EPA treatment when compared to 
megestrol acetate improved lean body mass221 and positively affected weight gain, survival and 
quality of life222. Unfortunately, findings surrounding the anti-cachectic effects of EPA can 
suffer from attrition and variability222.         
 Although cachexia has been seen to be a major determinant of quality of life and survival, 
it is important to state again there are currently no effective treatments for this skeletal muscle 
wasting disorder. The inability to have effective treatments likely stems from the insufficient 
knowledge of the underlying causal and biological mechanisms.  
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2.7 Rationale 
Although previous research has linked chemotherapy with the induction of cachexia, the 
mechanisms underlying this association are not completely understood.    
 The chemotherapy drug cocktail I used for my study consisted of 20μg/mL of cisplatin, 
50μg/mL of 5-Fluourouracil and 10μg/mL of leucovorin. I used these drug concentrations as 
similar drug concentration have been used recently and found to be effective in their ability to 
induce myotube atrophy160, 266. I combined chemotherapy drugs as this approach is common in 
the clinical setting today. This is because combining multiple chemotherapy drugs not only 
reduces drug toxicity and resistance126, but also results in a greater bioavailability of 
chemotherapy drugs127. Further, I treated myotubes with the chemotherapy drug cocktail once, 
similar to a clinical setting, in which cancer patients receive chemotherapy doses in single cycles 
lasting approximately 3-4 weeks133, 152. 
2.8 Objectives 
i. Examine the effect of a chemotherapy drug cocktail on myotube morphology, abundance 
of myofibrillar proteins and anabolic signalling mechanisms.  
ii. Study whether the associated loss of protein abundance is linked to altered rates of 
protein synthesis, mitochondrial content and glucose uptake in chemotherapy drug treated 
myotubes.  
2.9 Hypotheses 
i. A chemotherapy drug cocktail will have a negative effect on myotube growth and protein 
abundance.  
ii. A chemotherapy drug cocktail will cause a decrease in the rate of protein synthesis 
coinciding with reductions in mitochondrial content and glucose metabolism.  
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Chapter Four: Abstract        
 Cachexia, a condition prevalent in many chronically-ill patients, is characterized by 
weight loss and fatigue resulting from decreases in muscle mass and function. Although 
development of cachexia is associated with tumour burden and disease-related malnutrition, 
other studies have suggested a causative link between chemotherapy treatment and cachexia. In 
order to understand the mechanisms of chemotherapy-induced cachexia, we investigated the 
effects of a common chemotherapy drug cocktail on myotube morphology and myofibrillar 
protein abundance. On day 4 of differentiation, myotubes were treated with vehicle or a 
chemotherapy drug cocktail (a mixture of cisplatin (20μg/mL), leucovorin (10μg/mL), and 5- 
fluorouracil (50μg/mL)). Compared to myotubes treated with vehicle, those treated with the drug 
cocktail showed irregular myotube structure. Drug treatment also induced significant reductions 
in Myosin Heavy Chain (MHC) (n=5, p = 0.0003), troponin (n=4, p < 0.0001) and tropomyosin 
(n=4, p = 0.0059) by day 6 of differentiation. To explore the reasons for the low abundance of 
myofibrillar proteins, we examined treatment effects on mTORC1 (mammalian/mechanistic 
target of rapamycin complex1) signalling. Myotubes treated with the drug cocktail showed ~2-
fold reduction in the phosphorylation of mTORC1 activator AKTSer473 (n=4, p = 0.0058) and ~3-
fold reduction in phosphorylation status of mTORC1 substrates ribosomal protein S6Ser235/236 
(n=3, p = 0.0178) and its kinase, S6K1Thr389 (n=3, p = 0.0025). Drug treatments also led to 
reductions in protein synthesis, as well as further reductions in mitochondrial proteins 
cytochrome C oxidase (COX IV) and succinate dehydrogenase (SDHA) (n=4, p < 0.05). Lastly, 
due to reductions in phosphorylation of AKT, insulin-stimulated glucose uptake was measured 
and found to be reduced in myotubes treated with the drug cocktail (n=5, p = 0.06). The above 
findings suggest that it is critical to identify interventions that can limit the negative effects of 
these drugs on muscle protein status and mitochondrial content.  
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Chapter Five: Introduction        
 Cachexia, a condition affecting approximately nine million patients with chronic disease 
worldwide68, is characterized by detrimental loss of body weight and depletion of fat and muscle 
mass. In addition, this muscle wasting syndrome leads to wide scale fatigue and weakness, 
associated with decreases in quality of life and increased mortality and morbidity183, 184.  
 Maintenance of skeletal muscle mass is dependent on a balance between protein synthesis 
and protein degradation. These two processes are highly regulated by multiple signalling events 
and pathways within skeletal muscle. For example, activation of the insulin receptor substrate 1 
(IRS-1)/protein kinase B (AKT)/mechanistic target of rapamycin complex 1 (mTORC1) pathway 
is well-known to be vital for skeletal muscle growth and the inhibition of skeletal muscle protein 
degradation185. In opposition, stimulation of either the ubiquitin proteasome pathway (UPP) or 
autophagic mechanisms induce protein degradation within skeletal muscle186. Although upstream 
activators of the UPP, such as forkhead box protein O (FOXO) or nuclear factor kappa-light-
chain-enhancer of activated B cells (NFKB) are upregulated in atrophic conditions, signalling 
events and mechanisms in these pathways are yet to be completely understood.    
 Past reports have suggested that the development and severity of cachexia is due to the 
administration of chemotherapy drugs. Symptoms including nausea, vomiting, poor nutrition and 
anorexia-like states are often present following chemotherapy treatment. Of these, no side effect 
matches the debilitating loss of muscle mass, accompanying chemotherapy treatment regimens.  
 Although available evidence suggests an association between chemotherapy treatment 
and cachexia, the mechanisms of chemotherapeutic regimens in the promotion of cachectic 
symptoms are not completely clear. Cisplatin, a platinum containing chemotherapeutic, used in 
the treatment of testicular, ovarian, head, lung and neck cancers, dramatically increases muscle 
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atrophy f-box (MAFbx) and muscle ring finger-1 (MuRF1) in vivo158. In addition, cisplatin also 
activates nuclear factor kappa-light-chain enhancer of activated B cells (Nf-KB)159, linking this 
chemotherapeutic to the upregulation of the UPP in muscle. Other drugs, such as 5-Fluourouracil 
(5-Flu), part of Folfiri and Folfox chemotherapy regimens, upregulates p38 mitogen activated 
protein kinases (MAPK) resulting in weight loss, muscle loss and reductions in mitochondrial 
content160. Other common chemotherapy drugs, such as CPT-11 or Adriamycin promote tissue 
injury, either through increased production of inflammatory factors179 or reactive oxygen species 
(ROS)180.            
 Better understanding of the mechanisms underlying chemotherapy-induced cachexia may 
present possible regiments to increase the effectiveness of cancer treatment today. Prior to 
treatment, patients with greater accumulation of muscle mass may be presented with the 
opportunity for generally more aggressive chemotherapeutic treatment regimens. This 
opportunity may be lost in patients who have decreases in muscle mass. Therefore, patients with 
lower levels of muscle mass face the risk of drug toxicity, in accordance with decreased severity 
of treatment and chance of disease-free survival181, 182.      
 The purpose of this study was to investigate the factors of common chemotherapy drugs 
on the promotion of cachexia. In vitro, we explored the effects of a combinatory drug cocktail 
made up of chemotherapeutic agents cisplatin, 5-Flu and leucovorin. In this, we assessed L6 
myotube morphology, myofibrillar protein abundance and the modulation of anabolic signalling 
pathways. In addition, rates of protein synthesis, mitochondrial content and glucose metabolism 
were measured in drug exposed myotubes. Findings from this study present possible mechanisms 
of chemotherapy’s effect on muscle protein status, metabolism and mitochondria. 
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Chapter Six: Materials and Methods 
6.1 Reagents           
 α-Modification of Eagle’s Medium (AMEM) was purchased from Wisent (#310-010-
CL). Growth media (GM) was created by supplementing AMEM with 10% fetal bovine serum 
(FBS) from Gibco (#26050-088) and 1% Antibiotic-Antimycotic purchased from Wisent 
(#15240-062). Differentiation media (DM) was created by supplementing AMEM with 1% 
Antibiotic-Antimycotic and 2% horse serum (HS) purchased from Gibco (#26050088). 
Phosphate buffered saline (PBS) (#311-010-CL) and trypsin (#325-043-CL) were both purchased 
from Wisent. Protease inhibitor (#P8340) and phosphatase inhibitor (#P5726) were purchased 
from Sigma Aldrich. Dithiothreitol (DTT) was purchased from Research Organics (#2190D-
A101X). Chemotherapeutic drugs Cisplatin (#PHR1624-200MG) and 5-Flurouracil (#F6627-
1G), along with Folinic acid calcium salt hydrate (Leucovorin) (#F7878-500MG) were 
purchased from Sigma Aldrich. Dimethyl sulfoxide (DMSO) was purchased from Sigma Aldrich 
(#D5879-100ML). 1X DMEM lacking Methionine, Cysteine, L-Glutamine and sodium pyruvate, 
but supplemented with 4.5g/L D-Glucose was purchased from Gibco (#21013-024).  Radioactive 
35S express protein labelling mix was purchased from Perkin Elmer (#NEGO72007MC). [H3]-2-
deoxyglucose was purchased from Perkin Elmer (#NET549). Triton was purchased from MP 
Biomedicals, LLC (#M2528).  
6.2 Cell Culture          
 All experiments were completed using L6 rat skeletal muscle cell lines purchased from 
American Type Culture Collection. Cells were thawed from -80°C storage and cultured in T75 
flasks purchased from Gibco (#E18033C5). Cells were grown in 15mLs/flask of GM and placed 
in a cell culture incubator set at 37°C and 5% carbon dioxide. Once cells reached 70-80% 
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confluency, cells were incubated in trypsin for 5 minutes and passed by adding 200,000 cells into 
a new flask. Cells were then re-incubated for 48 hours until experiments were ready to begin. On 
experiment start dates (Day -2), cells were counted and seeded 2x105 (200,000) cells/well in 6-
well plates or 105 cells/well in 12-well plates. Cells were then left to incubate and proliferate for 
48 hours until the cells became 90-100% confluent. Once confluency was obtained (Day 0), cells 
were washed with 1mL/well PBS and shifted into 2mL/well of DM. Fresh DM was replenished 
every 24-48 hours until Day 4 when experiments were performed on myotubes.   
6.2.1 Formation of Chemotherapy Drug Cocktail and Cell Treatment   
 The chemotherapy drug cocktail used for all experiments was made up of a combination 
of three chemotherapeutic agents: Cisplatin, 5-Fluorouracil and Leucovorin. Stock 
concentrations were first made for each chemotherapy drug: 50mg Cisplatin dissolved in 1mL 
DMSO, 50mg 5-Flurouracil dissolved in 1mL DMSO and 20mg Leucovorin dissolved in 1mL 
DDH20. Each stock concentration was then aliquoted into 20μL, 30μL and 25μL amounts for 
Cisplatin, 5-Flurouracil and Leucovorin respectively. Each aliquot was than stored at -80°C until 
needed. DMSO was chosen as the suitable vehicle for all experiments as the drugs were 
dissolved in this solution. Upon thawing and using of each drug aliquot, the remaining amount 
was discarded. On Day 4, myotubes were separated into a drug or vehicle group. In the drug 
group, myotubes were exposed to fresh DM in conjunction with a chemotherapy drug cocktail 
consisting of 20μg/mL Cisplatin, 50μg/mL 5-Fluorouracil and 10μg/mL Leucovorin. Myotubes 
in the vehicle group were exposed to fresh DM supplemented with 1.4uL/mL of DMSO. The 
vehicle group served as control for all experiments. Myotubes were differentiated until day 7 for 
western blot analysis and day 6 for immunofluorescence, protein synthesis and glucose 
metabolism measurements.  
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6.3 Cell Harvesting         
 Myotube morphology was monitored by light microscopy daily and cell harvesting took 
place on Day 0, 4, 5, 6 and 7 for western blot analysis. Following washing with 1mL/well of 
PBS, 100 μL of lysis buffer [1mM EDTA, 2% sodium dodecyl sulphate (SDS), 25 mM Tris-
HCL pH 7.5, 10μL/mL protease inhibitor, 10μL/mL phosphatase inhibitor and 1mM DTT] was 
added to each well of the 6-well plate. A cell scraper was then used to collect the cells. In order 
to lyse the cells, all cell lysates were passed up and down using a 1mL syringe fitted with a 26-
guage needle. Each vehicle and drug lysate were then stored at -20°C for future analysis. Cell 
harvesting for protein synthesis and myotube fractionation are described below (See 6.5 and 6.6) 
6.4 Protein Assay, Gels and Western Blot Analysis     
 Following sample collection, the Pierce BCA Protein Assay Kit purchased from Thermo 
Scientific (#23225) was used to determine protein concentrations for each sample. Equal 
amounts of protein (~25μg) were then heated, vortexed and loaded into either 10% or 15% SDS-
page gels. Following gel electrophoresis, all proteins were transferred onto polyvinylidene 
difluoride (PVDF) membranes and left overnight at 4°C. The following day, the quality of 
transfer was measured by exposing each PVDF membrane to ponceauS (purchased from Sigma 
Aldrich, #81460) dye treatment for 15 minutes. In order to block non-specific antigen binding, 
membranes were incubated in a milk solution (5% milk powder in TBST) at room temperature 
for 1 hour. Each membrane then underwent a 3x5 minute wash in TBST followed by overnight 
incubation at 4°C in the primary antibody of interest. See table below.  
Primary Antibody Dilution Purchased From Secondary Antibody 
ph-S6K1thr389 1:1000 Cell Signaling #9205 Anti-rabbit (CST #7074) 
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ph-S6Ser235/236 1:1000 Cell Signaling #4858 Anti-rabbit (CST #7074) 
ph-AktSer473 1:1000 Cell Signaling #9271 Anti-rabbit (CST #7074) 
Gamma-Tubulin 1:1000 Sigma Aldrich #T6557 Anti-mouse (CST #7076) 
MHC 1:500 Developmental Hybridoma Anti-mouse (CST #7076) 
Troponin 1:400 Developmental Hybridoma Anti-mouse (CST #7076) 
Tropomyosin 1:400 Developmental Hybridoma Anti-mouse (CST #7076) 
COX IV 1:1000 Cell Signaling #4850 Anti-rabbit (CST #7074) 
Succinate Dehydrogenase 1:1000 Cell Signaling #11998 Anti-rabbit (CST #7074) 
HSP60 1:1000 Cell Signaling #12165T Anti-rabbit (CST #7074) 
GAPDH 1:1000 Cell Signaling #2118S Anti-rabbit (CST #7074) 
                                                                                                                                                           
Following the overnight incubation in primary antibody, membranes went through a second 3x5 
minute wash in TBST. Anti-rabbit (CST #7074) and Anti-mouse (CST #7076) antibodies 
purchased from Cell Signaling Technologies were diluted in the milk solution described earlier 
at a dilution of 1:10000. Each membrane was then incubated in the corresponding secondary 
antibody for 3 hours at room temperature. Following the 3 hour incubation time, membranes 
were washed 3x5 minutes in TBST. Lastly, HRP chemical luminescent substrate purchased from 
BioRad (#1705060S) was applied to each membrane and BioRad ChemiDoc XRS+ was used for 
signal visualization. Images were quantified using image lab software v7. 
6.5 Protein Synthesis Measurement in Myotubes      
 On Day 5 and Day 6 of treatment, vehicle and drug treated myotubes were exposed to a 
protein synthesis labelling mix consisting of 1mL/well of 1X DMEM lacking Methionine and 
Cysteine, 2μci/mL of 35S protein labelling mix and 2% Dialyzed FBS (DFBS). Each well 
44 
 
received 1mL of the protein synthesis labelling mix and was then placed in the cell culture 
incubator for 1 hour. Following the 1 hour, the incubation media (1mL) from each well was 
collected and later counted for scintillation to ensure equal levels of radioactivity in each well. 
Each well then underwent 5X washes in 1mL/well of ice cold PBS to wash away any 35S residue 
on the cell surface. The steps for cell harvesting including the addition of lysis buffer and cell 
scraping then commenced, similar to that of Western Blot Analysis (See 6.3).   
 Protein assay, creating gels and gel electrophoresis for western blot analysis of proteins 
have all been described previously (See 6.4). Following gel electrophoresis on a separate pair of 
gels, gels were stained with Comassie Bright Blue Solution for 1 hour (0.1g Comassie Blue R-
250 dissolved in 100ml of methanol, acetic acid and DDH20 solution). Following the 1 hour 
Comassie blue staining, 4x15minute washes with a distaining solution (60% DDH20, 20% 
Methanol, 10% Glacial Acetic Acid) was used to wash the Comassie blue solution away. 
Overnight incubation at 4°C in the distaining solution then commenced. The following day, a 
Comassie blue blot (CBB) of the stained membrane was taken by the Typhoon FLA 9500 imager  
and the gel was then dried for 1 hour using a Model 583 Gel Dryer from BIO-RAD. Gels were 
dried in between a piece of filter paper and saran wrap. 1 hour later, the dried gel (with 
radioactive samples/proteins within) was placed inside an autoradiography cassette (FBCA 810) 
purchased from Fisher Scientific and exposed to a 20x25cm phospho imaging screen purchased 
from Fujifilm (#An28956475) for 1-2 weeks. Following the exposure period, the imaging plate 
was imaged using Typhoon FLA 9500 imager. Typhoon FLA 9500 software program was used 
for signal visualization and images were quantified using Quantity One software from BIO-
RAD.    
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6.6 Myofibrillar and Sarcoplasmic Fractionation of Myotubes    
 On day 5 and 6 of treatment, vehicle and drug-treated wells were incubated for 1 hour in 
a protein synthesis mix described previously. Three drug and three vehicle treated wells were 
then incubated in trypsin for 5 minutes and cells were collected into one 15mL test tube per 
condition. 15mL tubes were then centrifuged at 2000rpm for 5 minutes, washed and then re-
suspended in 500μL/tube of a Triton solution (PBS, 1% Triton, 10μL/mL protease inhibitor, 
10μL/mL phosphatase inhibitor, 1mM EDTA). Of the 500μL Triton solution, 100μL was 
extracted and set aside for protein assay measurement. Fractionation began by centrifuging the 
triton solution (now 400μL) at 1200g for 5 minutes followed by the removal and storage of the 
sarcoplasmic (supernatant) portion. Steps were then taken to prepare a concentrated myofibrillar 
sample (See Appendix A for full procedure). Gel electrophoresis, western blot analysis, comassie 
blue staining and protein synthesis measurement procedures described previously (see 6.4 and 
6.5) were than completed.  
6.7 Immunofluorescence Microscopy       
 L6 myoblasts were seeded into 12-well plates and grown on top of cover slips purchased 
from Fisher Scientific (#092815-9). Once 90-100% confluency was reached (Day 0), cells were 
washed and shifted into DM until Day 4 of differentiation. On Day 4, myotubes were exposed to 
fresh DM in conjunction with either Vehicle or Drug treatment. On Day 5 and 6 of 
differentiation, cover slips with cells were fixed with 1mL/well of a paraformaldehyde (PFA) 
solution (4% PFA in PBS), permeabilized with 1mL/well of a Triton solution (0.03% Triton X-
100 in PBS) and incubated with 400μL/well of a blocking solution (10% horse serum in PBS). 
Cover slips were then exposed overnight to 500μL/well of diluted MHC primary antibody 
solution (2.5μg/ml of MHC in 1% BSA in PBS). The following day, cover slips were washed 
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3x5minutes with PBS and then exposed to 500μL/well of a diluted Texas Red anti-mouse IgG 
secondary antibody before DAPI staining (for nuclei) and cover slip mounting on a microscope 
slides. Slides were then imaged using the EVOS FL Auto microscope from Life Technologies 
along with the EVOS FL Auto program for signal capturing and exposure (See Appendix B for 
full procedure). For quantification purposes, all images were transformed into an 8-bit gray scale 
image and mean gray value of each sample was measured within a 0-255 range using image j.  
6.8 2-Deoxy-Glucose Uptake in Myotubes      
 2-deoxyglucose (2-DG) was used for all glucose uptake assays. This is due to the fact that 
once 2-DG is taken up into the cell, it cannot be fully metabolised and accumulates within the 
cell. By using radiolabelled 2-DG ([3H]-2-deoxyglucose), both the radioactively tagged 2-DG 
and unlabelled 2-DG can enter the cell. Therefore, by measuring the level of radioactivity within 
cells, we can determine the levels of glucose uptake either with or without the presence of 
insulin.            
 L6 myoblasts were seeded into 12-well plates until 90-100% confluency was reached 
(Day 0). On Day 0, cells were washed and shifted into DM until Day 4 of differentiation. On 
Day 4, myotubes were exposed to fresh DM in conjunction with either Vehicle or Drug 
treatment. On Day 5 and 6 of differentiation, myotubes in both conditions were incubated in 
starvation media (complete starvation medium, free of amino acids and serum), plus their 
respective treatments for three hours. Following the three hour starvation period, myotubes in 
each condition were incubated with or without 100nM of insulin diluted in starvation media and 
their respective vehicle or drug treatments for 20 minutes. Post 20 minute insulin exposure, cells 
were rinsed 2X in HEPES (4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid) buffered saline 
and then incubated for 5 minutes at 37.1°C in 300μL of transport solution (HEPES buffer, 10μM 
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2-deoxyglucose, 0.5 μCi/mL [3H]-2- Deoxyglucose). After 5 minutes, the glucose uptake 
reaction was stopped through constant exposure to ice and by washing the cells 3X in ice-cold 
stop solution (1ml/well of 0.9% Saline). 1mL of 0.05M NaOH was then added to the cells for 
scraping and collection. Two-hundred μL was set aside and frozen at -20°C for future protein 
assay analysis. The leftover 800μL was pipetted into scintillation fluid (Ecolite+, MP 
Biomedicals #01882475) and respectfully labelled scintillation tubes (see Appendix C for full 
procedure). A liquid scintillation counter (Tri-Carb Liquid Scintillation Counter) was used to 
count and measure the radioactivity from samples in each vial. Protein assay protocol (described 
above) and results were than used and rate of glucose transport was expressed picomole per μg 
of protein.     
6.9 Graphical Representation of Western Blots and Statistics 
 Western blotting for MHC, troponin, tropomyosin, P-AKT, P-S6K1, P-S6, COXIV, 
SDHA and HSP60 were adjusted by their respective gamma tubulin values and then normalized 
to the Vehicle group on Day 5. All graphs were designed using Prism Computer Software 
Version 7.  
 Unpaired t-tests with a welch-correction was used to analyze immunofluorescence results 
and to compare D0 myoblasts to D4 myotubes. Two-way ANOVA across all groups was used to 
compare vehicle and drug treated myotubes on Day 5, 6 and 7, as well for glucose uptake results 
to measure the significance of differences followed by a Tukey’s Post-Hoc Test. Differences 
were found to be significant when p-value < 0.05. All results expressed as means ± SEM. 
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Chapter Seven: Results 
A chemotherapy drug cocktail negatively regulates myotube formation and morphology 
 Due to the literature outlining the negative relationship between chemotherapy treatment 
and skeletal muscle158, 160, I examined the effect of a chemotherapy drug cocktail on L6 myotube 
formation. On Day 0, control myoblasts (Fig.1A) were co-treated with fresh DM and either 
DMSO (Vehicle) or a chemotherapy drug cocktail (Drug). By day 4 of differentiation, myoblasts 
exposed to the chemotherapy drug cocktail did not form myotubes likely due to reductions in cell 
number (Fig.1B). Due to the inability of chemotherapy drug-treated myoblasts to grow and 
differentiate, I turned to investigate the effect of the chemotherapy drug cocktail on myotubes 
differentiated over four days. I also believed that adding the drug to fully formed myotubes 
would present a more real life scenario as patients undergoing chemotherapy treatment have 
functionally formed muscle prior to treatment. On day 4, control myotubes (Fig.1C) were treated 
with fresh DM and either vehicle or drug treatments. By day 5 of differentiation, myotubes 
treated with the drug cocktail began to show small, but noticeable abnormalities in myotube 
structure compared to vehicle (Fig.1D). Forty-eight (Fig.1E) and 72 (Fig.1F) hours after 
commencement of drug treatment, abnormalities in myotube morphology were aggravated. Due 
to the possibility that the myotubes treated with the drug cocktail may exhibit disruptions in total 
protein concentration, I next measured and compared the protein concentrations of each 
treatment. Although protein concentration significantly differed between D0 myoblasts and D4 
myotubes (n=4, p = 0.006), there were no significant differences found with regards to protein 
concentrations in vehicle and drug-treated myotubes on Day 5, 6 and 7 (Fig. 1G). Although the 
evidence presented here is clear on the negative effect of a chemotherapy drug cocktail on 
myotube morphology, the mechanisms behind this relationship remain unclear. 
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A chemotherapy drug cocktail disrupts L6 myofibrillar abundance    
 Due to the significant morphological changes observed under light microscopy in 
myotubes treated with the drug cocktail (Fig. 1), I next used immunofluorescence to examine the 
expression of myosin heavy chain (MHC). MHC staining of vehicle and drug treatments is 
shown in both D5 and D6 treated myotubes (Fig 2A). On day 5 of differentiation, a small non-
significant decrease is seen in MHC staining of myotubes treated with the drug cocktail (Fig 2B). 
However, by Day 6 of differentiation, detrimental loss of myofibrillar abundance, shown through 
a significant decrease in MHC staining (n=4, p = 0.0209) is present in the drug group compared 
to vehicle (Fig. 2C). DAPI staining of nuclei is equal in both treatments across both days of 
differentiation (Fig. 2A-C). Coinciding with the images seen under light microscopy, the drug 
cocktail is clearly having a negative effect on L6 myofibrillar abundance.   
Myofibrillar protein content is decreased in myotubes treated with a chemotherapy drug cocktail 
 Due to the negative effect of the drug cocktail on MHC staining (Fig. 2), I next 
investigated via western blotting, the abundance of myofibrillar proteins MHC, troponin and 
tropomyosin. Compared to myotubes treated with vehicle, those treated with the drug cocktail 
showed significant reductions in MHC (n=5, p = 0.0003), troponin (n=4, p < .0001) and 
tropomyosin (n=4, p = 0.0059) by day 6 of differentiation. By day 7 of differentiation, myotubes 
treated with the drug cocktail showed significant reductions in MHC (n=5, p < .0001), troponin 
(n=4, p < 0.0001) and tropomyosin (n=4, p = 0.0095) compared to vehicle (Fig.3A-C). This data 
demonstrates that the abnormalities in myotube structure caused by the drug cocktail may be 
attributed to a decrease in the levels of myofibrillar protein content.  
mTORC1 signalling is disrupted in myotubes treated with a chemotherapy drug cocktail  
 I next sought to investigate factors associated with the decrease in myofibrillar proteins 
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found in myotubes treated with the drug cocktail. I examined proteins involved in signalling 
towards mTORC1, a master regulator of protein synthesis. Upstream activator AKT, along with 
two key downstream substrates S6 and S6K1 were the signalling proteins examined to help 
determine mTORC1 activity (Fig.4). Compared to D0 myoblasts, phosphorylation of AKTSer473, 
S6Ser235/236 and S6K1Thr389 were all increased in D4 myotubes (Fig. 4A-C). Compared to 
myotubes treated with vehicle, those treated with the drug cocktail showed significant reductions 
in the phosphorylation of AKTSer473 (n=4, p = 0.0058), S6Ser235/236 (n=3, p = 0.0178) and 
S6K1Thr389 (n=3, p = 0.0025) by day 6 of differentiation. By day 7 of differentiation, myotubes 
treated with the drug cocktail showed significant decreases in the phosphorylation of AKTSer473 
(n=4, p < 0.0001), S6Ser235/236 (n=4, p = 0.0309) and S6K1Thr389 (n=4, p = 0.0190) (Fig.4A-C). 
The data presented shows that a decrease in myofibrillar protein content may be a result of a 
decrease in mTORC1 activity.  
Protein synthesis is reduced in myotubes treated with a chemotherapy drug cocktail  
 Although myotubes treated with the drug cocktail exhibited significant decreases in 
mTORC1 signalling (Fig. 4), it is still undetermined whether this relationship is due to a 
decrease in protein synthesis or an increase in proteolysis. Therefore, I next measured the rate of 
protein synthesis in myotubes treated with the drug cocktail using 35S Methionine incorporation. 
On both Day 5 and 6 of differentiation, myotubes under drug treatment showed a decrease in the 
levels of 35S methionine incorporation into proteins compared to vehicle (Fig. 5A), signifying a 
decrease in protein synthesis. Protein concentrations in both treatment groups are shown across 
both days of differentiation represented by the γ-tubulin blot (Fig. 5B) and the comassie blue blot 
(CBB) (Fig. 5C). Due to the equal concentrations of protein in each treatment, these results point 
to a decrease in the rates of total protein synthesis in myotubes treated with the drug cocktail.  
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Protein synthesis is decreased in fractionated myotubes treated with a chemotherapy drug cocktail 
 Due to the negative effect of the drug cocktail on myofibrillar protein abundance (Fig.3), 
I next wanted to determine whether the decrease in total protein synthesis (Fig.5), was specific to 
myofibrillar and sarcoplasmic fractions. I therefore fractionated L6 myotubes from both 
treatments into three fractions: total lysate (Load), Myofibrillar (Myofib) and sarcoplasmic 
(Sarco) fractions. We then measured the rates of protein synthesis using 35S Methionine 
incorporation. On both Day 5 and 6 of differentiation, levels of 35S Methionine incorporation 
were decreased in all drug treated fractions compared to vehicle (Fig 6A). In accordance with the 
above protein synthesis results, protein concentrations in both treatment groups were equal 
across both days of differentiation represented by the γ-tubulin blot (Fig. 6C) and CBB blot (Fig. 
6B). Successful fractionation of myotubes was identified via western blotting of MHC for 
myofibrillar fractions and GAPDH for sarcoplasmic fractions (Fig. 6C).  
Mitochondrial Proteins are reduced in myotubes treated with a chemotherapy drug cocktail 
 I next investigated the modulation of mitochondrial proteins as mitochondrial proteins are 
associated with skeletal muscle maintenance and growth. Compared to D0 myoblasts, Succinate 
Dehydrogenase and COXIV, but not HSP60 were increased in D4 myotubes (Fig. 7A-C) 
Compared to myotubes treated with vehicle, those treated with the drug cocktail showed a 
significant decrease in Succinate Dehydrogenase (n=4, p = 0.0018) by day 6 of differentiation 
(Fig. 7A). By day 7 of differentiation, myotubes treated with the drug cocktail exhibited 
decreases in COX IV (n=4, p < 0.0001) and Succinate Dehydrogenase (n=4, p < 0.0001) 
compared to vehicle (Fig. 7A-B). Interestingly, myotubes treated with the drug cocktail showed a 
significant increase in HSP60 (n=3, p = 0.0053) by day 6, but not day 7 of differentiation 
compared to vehicle (Fig. 7C).  
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Glucose Uptake is reduced in myotubes treated with a chemotherapy drug cocktail  
 Due to the presence of GLUT4 in L6 muscle cells and the finding that the 
phosphorylation status of AKT was reduced in myotubes treated with the chemotherapy drug 
cocktail (Fig. 4A), I next investigated insulin stimulated glucose uptake in both treatment groups. 
By day 5 of differentiation, there were no differences in the levels of glucose uptake across 
treatments (Fig. 8A). In contrast, by day 6 of differentiation, myotubes treated with the 
chemotherapy drug cocktail exhibited reductions in insulin-stimulated glucose uptake (n=5, p < 
0.06) compared to vehicle (Fig. 8B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
Figure Results 
Figure 1. 
G
) 
Fig 1. A chemotherapy drug cocktail negatively regulates myotube formation and 
morphology. A: D0 L6 myoblasts were exposed to fresh DM supplemented with either 
Vehicle or Drug treatments. B: Vehicle or drug treated myoblasts differentiated for four days 
C: Formation of D4 myotubes prior to vehicle or drug treatments. D-F: Vehicle and drug 
treated myotubes on D5 (D), D6 (E) and D7 (F) G: Protein Concentration (μg/μL) 
differences between D0 control myoblasts, D4 control myotubes and D5, D6 and D7 vehicle 
and drug treated myotubes. (n=4 independent experiments, 3 replicates per experiment). Bar 
graphs show mean ± SEM.  
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Figure 2. 
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Fig 2. A chemotherapy drug cocktail disrupts L6 myofibrillar abundance. L6 myoblasts were 
differentiated until day 4. On day 4, myotubes were co-treated with fresh DM and either 
Vehicle or a chemotherapy drug cocktail until day 5 and 6. A: D5 and D6 myotubes in both 
treatments were fixed, permeabilized, blocked and incubated overnight in MHC primary 
antibody. Next, cells were exposed to Texas Red Anti-Mouse secondary antibody before 
mounting. DAPI was used to identify the nuclei. Bar, 400μm. B-C: Quantified mean gray 
value of MHC and DAPI nuclei staining in vehicle and drug treated myotubes on day 5 and 6 
of differentiation. (n=4 independent experiments, 3-4 replicates per experiment, * denotes 
significance, p < 0.05). Bar graphs show mean ± SEM. 
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Fig 3. Myofibrillar protein content is decreased in myotubes treated with a chemotherapy 
drug cocktail. L6 myoblasts were differentiated until day 4. On day 4, myotubes were co-
treated with fresh DM and either Vehicle or a chemotherapy drug cocktail until day 7. 
Chemotherapy drug treated myotubes had decreased abundance of myofibrillar protein 
content of MHC (A), Troponin (B) and Tropomyosin (C) throughout differentiation. (n=4-5 
independent experiments, 3 replicates per experiment, * denotes significance, p < 0.05). Bar 
graphs show mean ± SEM.  
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Fig 4. mTORC1 signalling is disrupted in myotubes treated with a chemotherapy drug 
cocktail. On day 4, myotubes were co-treated with fresh DM and either Vehicle or a 
chemotherapy drug cocktail until day 7. Phosphorylation of mTORC1’s upstream activator 
AKT (A) was decreased in the drug group throughout differentiation. Phosphorylation of 
mTORC1’s downstream targets S6 (B) and S6K1 (C) were decreased in the drug group 
throughout differentiation. (n=3-4 independent experiments, 3 replicates per experiment, * 
denotes significance, p < 0.05). Bar graphs show mean ± SEM.  
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Fig 5. Protein Synthesis is reduced in myotubes treated with a chemotherapy drug cocktail. 
L6 myoblasts were differentiated until day 4. On day 4, myotubes were co-treated with fresh 
DM and either Vehicle or a chemotherapy drug cocktail until D6. On D5 and D6, myotubes in 
both treatments were incubated in a 35S Methionine labelling mix for 1hour, washed 5X in 
1mL/well of PBS and then harvested according to regular procedure. A: D5 and D6 
representative blot of 35S Methionine incorporation into proteins in vehicle and chemotherapy 
drug treated myotubes B: Loading control blot for γ-tubulin in D5 and D6 vehicle and 
chemotherapy drug treated myotubes. C: Comassie blue blot (CBB) of protein concentrations 
in D5 and D6 vehicle and chemotherapy drug treated myotubes. (n=5 independent 
experiments, 3 replicates per experiment)  
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Fig 6. Protein synthesis is decreased in fractionated myotubes treated with a chemotherapy 
drug cocktail. Day 4 differentiated myotubes were co-treated with fresh DM and either 
Vehicle or a chemotherapy drug cocktail until day 6. On D5 and D6, myotubes in both 
treatments were incubated in a 35S Methionine labelling mix for 1hr. Next, myotubes were 
fractionated into vehicle load, drug load, vehicle myofibrillar, drug myofibrillar, vehicle 
sarcoplasmic and drug sarcoplasmic. A: D5 and D6 representative blot of 35S Methionine 
incorporation into proteins in vehicle and chemotherapy drug treated myotubes for each 
fractionated segment. B: Comassie blue blot (CBB) of protein concentrations in D5 and D6 
vehicle and chemotherapy drug treated fractionated myotubes. C: Representative western 
blotting for MHC, GAPDH and γ-tubulin showing protein expression specific to each 
fractionated segment. (n=4 independent experiments). Myofib = Myofibrillar, Sarco = 
Sarcoplasmic. 
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Fig 7. Mitochondrial Proteins are reduced in myotubes treated with a chemotherapy drug 
cocktail A: L6 myoblasts were differentiated until day 4. On day 4, myotubes were co-treated 
with fresh DM and either vehicle or a chemotherapy drug cocktail until day 7. A-B: By D7 of 
differentiation, mitochondrial proteins SDHA (A) and COXIV (B) were decreased in 
chemotherapy drug treated myotubes compared to vehicle. C: HSP60 protein content in 
vehicle and chemotherapy drug treated myotubes. (n=3-4 independent experiments, 3 
replicates per experiment, *denotes significance, p < 0.05). Bar graph shows mean ± SEM.  
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Fig 8. Glucose Uptake is reduced in myotubes treated with a chemotherapy drug cocktail. L6 
myoblasts were differentiated until day 4. On day 4, myotubes were co-treated with fresh DM 
and either Vehicle or a chemotherapy drug cocktail. On D5 (A) and D6 (B), myotubes in all 
conditions were starved for 3 hours, followed by incubation with or without insulin for 20 
minutes. Next, cells were washed in hepes buffer and incubated in transport solution for 5 
minutes. Cellular glucose uptake was stopped using ice cold saline and cells were harvested 
using NaOH. (n=5 independent experiments, 2-5 replicates per experiment). Bar graph shows 
mean ± SEM.  
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Chapter Eight: Discussion 
The findings from this study suggest that common chemotherapeutic agents cisplatin and 
5-Flu, normally used for the treatment of a spectrum of different cancers, leads to abnormal 
myotube morphology and protein metabolism. The observed myotube abnormalities under drug 
treatment are associated with reductions in the abundance of myofibrillar proteins, anabolic 
signalling, protein synthesis, mitochondrial content and glucose uptake.     
 To our knowledge, this study is the first to investigate the effects of a common 
chemotherapeutic drug cocktail on myofibrillar protein content in L6 cells. In this, the present 
study has found evidence of chemotherapy-related effects on myofibrillar protein integrity in 
myotubes. Compared to vehicle, I have shown that myotubes treated with the drug cocktail 
exhibit concurrent loss in the immunofluorescent expression of MHC (Fig 2). I next measured 
and quantified DAPI nuclei staining in both treatments to ensure that cell number was similar 
and that the above finding was not due to factors such as cell death or unspecific binding. Via 
western blotting of MHC, troponin and tropomyosin, I further confirmed the reductions in 
myofibrillar protein abundance in myotubes treated with the drug cocktail (Fig 3). Due to the 
observation that chemotherapy treatment decreases body weight, associated with reductions in 
muscle mass and function160, this finding is potentially critical as myofibrillar proteins are 
necessary for muscle maintenance and contraction over time187.        
 I suggest that the reduction in myofibrillar proteins induced by the administration of 
chemotherapy drugs, can be attributed to reductions in anabolic signalling pathways. Both 
upstream and downstream markers in the IGF-1/AKT/mTORC1 pathway were decreased in 
myotubes following the administration of chemotherapy drugs (Fig 4). Our findings for 
decreased activity through the IGF-1/AKT/mTORC1 pathway in myotubes following drug 
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administration is in opposition to other cachectic models. In cachectic tumour-bearing models, 
upregulation of AKT is associated with progressive tumour growth and inhibiting AKT does not 
affect mTORC1/S6 signalling188 in muscle. Similarly, the phosphorylation of AKT is also 
significantly upregulated in denervation-induced muscle atrophy, but mTORC1’s downstream 
substrate S6K1 is downregulated189. Our results in accordance with these past reports, present 
clear complexities on the effect of cachexia on skeletal muscle anabolism through mTORC1 
regulation. These findings suggest that the IGF-1/AKT/mTORC1 pathway may be differentially 
regulated by AKT substrates or by separate oncogenic and protein degradation networks during 
cachexia.            
 Since mTORC1 regulation is involved in both augmenting skeletal muscle anabolism and 
inhibiting protein degradation185, I investigated whether the deregulated mTORC1 following 
drug administration had an effect on protein synthesis in myotubes. Using 35S methionine 
incorporation (Fig. 5), I suggest that the reductions in activity through the AKT/mTORC1 
pathway is associated with decreases in protein synthesis. I further confirmed our myofibrillar 
protein findings (Fig. 2-3), by fractionating myotubes into myofibrillar and sarcoplasmic 
segments. In accordance to decreases in total protein synthesis (Fig. 5), I found evidence of 
reduced protein synthesis in myofibrillar and sarcoplasmic portions of myotubes (Fig. 6). These 
findings coincide with the effects of other chemotherapeutic drugs, such as doxorubicin, which 
also impairs skeletal muscle protein synthesis in vivo190, 191.    
 Findings from this study also found support for chemotherapy-induced effects on 
mitochondrial content in myotubes. Following drug treatment, myotubes exhibited mitochondrial 
complex depletion of COXIV and SDHA (Fig 7). COXIV and SDHA are two subunits within the 
electron transport chain that allow for essential generation of ATP. Dysregulation within the 
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complexes of the electron transport chain, leads to the insufficient production of ATP and the 
formation of reactive oxygen species192, a well-known factor in the progression of cachexia93, 96. 
Our mitochondria observations are consistent with previous work whereby cachexia-induced 
chemotherapy treatment led to skeletal muscle alterations associated with mitochondrial 
abnormalities160. Although mitochondria protein content can often be correlated with 
mitochondrial activity, our study did not investigate this mechanism and elucidations cannot be 
made at this time. In contrast, the previous study mentioned found both mitochondria number 
and activity to be downregulated in response to chemotherapy drugs. Further, I also found 
evidence of increased HSP60 protein content in myotubes administered the drug cocktail (Fig. 
7). Within healthy or unstressed mitochondria, HSP60 is a chaperone mediating protein involved 
in transportation and re-folding of proteins from the cytoplasm to the mitochondrial matrix193. 
Interestingly, similar to the increase in HSP60 following drug administration, past reports have 
found evidence of increases in the levels of heat shock proteins in cellular stressing conditions, 
such as exercise and oxidative stress197, 198, but few past reports have studied HSPs following 
chemotherapy treatment. From these past reports, HSP60 mRNA expression was closely related 
to the development of cisplatin resistance in vitro251. In addition, inhibition of heat shock protein 
27 (HSP27) phosphorylation resulted in increased 5-FLU sensitivity in-vitro252. 
 Lastly, via glucose uptake measurement assays, I find evidence of myotube alterations in 
insulin stimulated glucose uptake following chemotherapy drug administration. The mechanism 
of glucose uptake in skeletal muscle is a tightly regulated process involving multiple signalling 
events and proteins. Activation of IRS-1 by the binding of insulin to the α-subunit of its cognate 
insulin receptor leads to the activation of the PI3K pathway194. Via the phosphorylation of 
AKT195, the PI3K pathway culminates the translocation of glucose transporter 4 to the cell 
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surface, thereby promoting glucose uptake196. Due to the vital role of AKT in insulin mediated 
glucose uptake and the fact that chemotherapy drugs decreased the phosphorylation of this 
kinase (Fig 4), I investigated glucose uptake in myotubes treated with the chemotherapy drug 
cocktail. Similarly to the phosphorylation of AKT, insulin stimulated glucose uptake was 
reduced in myotubes following drug treatment (Fig 8). This finding is similar to past reports 
whereas doxorubicin treatment decreased insulin-stimulated glucose uptake in L6 cells253, but 
this study did not explore a mechanism related to AKT in-vitro. This finding is particularly 
important since individuals receiving chemotherapy treatment with pre-existing diabetes are at 
an increased risk of developing glycemic issues in accordance with an increased risk of death199. 
I suggest that the mechanism of decreased glucose uptake following administration of 
chemotherapy drugs in myotubes may be a result of decreased phosphorylation of AKT, but may 
also be partly due to a decrease in muscle protein status.       
 The present report does not come without study limitations that should be addressed. 
Although protein concentrations do not differ significantly, L6 myotubes often struggle to 
continually differentiate past 7 days. This provides a limited period of time to measure proteins 
and markers of interest. Nonetheless, we were still able to measure proteins and markers of 
interest on day 5, 6 and 7. Another possible limitation is the fact that the chemotherapy drugs and 
their effects were not studied individually and the singular effects of these drugs on myotube 
morphology and protein metabolism cannot be elucidated at this time. Whereas others have 
studied the effects of singular drugs156, 179, the goal of my study was to investigate the combined 
effects of chemotherapy drugs in myotubes. In addition, due to the fact that total protein levels 
for AKT, S6K1 and S6 were not investigated, it is a possibility that the observed decreases in the 
phosphorylation of these signals is due to a decrease in total protein content. Further, due to the 
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decreases in γ-tubulin following drug treatment on day 6 and 7, findings from this study could be 
attributed to the effect of the chemotherapy drug cocktail on cell death. Although this effect of 
cell death may be true, all findings were normalized to their respective γ-tubulin values. In 
addition, significant decreases were still found for troponin, tropomyosin and p-S6K1 by day 5 
of differentiation, when γ-tubulin values did not differ between treatments. In regards to our 
cachexia model, using an in-vitro approach does not allow for elucidation of how these 
chemotherapy drugs effect mammalian body systems. In addition, our chemotherapy-induced 
cachexia model may underlie cachexia severity, as cachexia development is often caused my 
multiple factors such as tumour burden, malnutrition and muscle disuse. Nonetheless, our in-
vitro model allows for the investigation of specific mechanisms underlying chemotherapy-
induced cachexia progression and development in isolated conditions.    
 Nonetheless, data from this study finds evidence of chemotherapy related effects on 
myofibrillar protein abundance, anabolic signalling, protein synthesis, mitochondrial content and 
glucose metabolism. Findings shed light on a possible mechanism of chemotherapy-driven 
cachexia development and progression. Interventions aimed at the maintenance of muscle mass 
during chemotherapy treatment may increase body weight, associated with increases in treatment 
efficacy, quality of life and chance of survival.  
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Chapter Nine: Future Research 
Future investigations should include: 
1) Since we explored and found decreases in anabolic signaling (mTORC1) and protein 
synthesis (35S methionine incorporation), future studies should investigate markers 
and pathways of protein degradation in myotubes treated with the chemotherapy drug 
cocktail. Experiments investigating protein content (western blotting) and mRNA 
expression (RT-PCR) of autophagy (ULK-1, LC3B I/II, Beclin-1) and muscle atrophy 
(MuRF-1, MAFbx) related markers should be conducted in myotubes treated with the 
chemotherapy drug cocktail.  
2) Due to the fact that we used 35S methionine (an amino acid) to measure protein 
synthesis in myotubes, future studies should confirm these results by investigating 
amino acid uptake and transport in myotubes treated with the chemotherapy drug 
cocktail. These experiments could be conducted by using high pressure liquid 
chromatography to measure both the transport and concentration of amino acids in 
myotubes treated with the chemotherapy drug cocktail. 
3) In accordance with seeing a decrease in mitochondrial proteins (SDHA, COXIV), 
future studies should also measure mitochondrial activity in myotubes treated with 
the chemotherapy drug cocktail. Since disruptions in mitochondria activity are 
associated with increases in ROS262 and ROS is a factor regulating cachexia93, 
investigating mitochondrial activity will help to determine whether myotubes treated 
with the chemotherapy drug cocktail are affected by ROS. 
4) Investigate mechanisms of chemotherapy-induced cachexia in an in-vivo model. By 
investigating similar mechanisms of our in-vitro study within an animal model, 
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findings could elucidate the mechanisms of chemotherapy-induced cachexia in 
mammalian body systems. Using an animal model also allows the investigation of 
chemotherapy-induced cachexia on age and gender.  
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Appendices 
Appendix A - Myofibrillar and Sarcoplasmic Fractionation of Myotubes 
1. Suck media from each well, add 500μL trypsin into each well, swish around and incubate 
for 5 minutes. 
2. May need to scrape the wells to unstick myotubes. Add 2mLs PBS into each well. 
3. Combine three wells of the same condition together and add combined well into 1 15mL 
test tube. 
4. Centrifuge each 15mL test tube at 2000rpm for 5 minutes. 
5. Take out 15mL test tubes out and suck media, but leave pellet. Do this for all. Resuspend 
pellet in 1mL PBS and break up the pellet. Spin down again, same speed and time. 
6. Take 15mL test tubes from centrifuge, suck media but leave the pellet. Resuspend pellet 
from each 15mL tube into 500μl of triton solution. Triton Solution: 
- Triton (1% Triton per xmL of PBS) 
- Protease Inhibitor 10μL/mL 
- Phosphatase Inhibitor 10μL/mL 
- EDTA (Add to 1mM) 
7. Each 15mL tube will now have 500μL of triton mixture in it. Need 2 eppendorf tubes for 
each 15mL test tube. 1 will be labelled protein assay/loading control, 2 is for 
sarcoplasmic/Myofibrillar amounts.  
Pipette the full 500μL from the 15mL tube (mixed well) into eppendorf tube number 2. 
Do this for all and syringe the mixture up and down to break it up. Then take 100μL from 
eppendorf tube 2 and put in eppendorf tube 1 labelled protein assay/loading control.  
Place the 100μL aliquot (eppendorf tube 1) into -20 freezer. 
8. Centrifuge eppendorf tube 2 (400μL) at 1200g (RCF 12.0) for 5 minutes. Use the fridge 
centrifuge.  
9. Need more eppendorf tubes. Label them sarcoplasmic. Need a sarcoplasmic eppendorf 
tube for each eppendorf tube that we are centrifuging. The supernatant (400μL) will be 
the sarcoplasmic fraction while the pellet will be our Myofibrillar. Take a 400μL aliquot 
and add it into our eppendorf tube labelled sarcoplasmic and place in -80 degree. Put 
Myofibrillar on ice for now. 
10. Grab the MPI buffer from the 4 degree fridge. Need 300μL of the buffer for each sample. 
Also need 10μL/mL of protease inhibitor.  
11. Add 300μL of the buffer we made onto the Myofibrillar pellet. Break down the pellet into 
the buffer and leave in fridge on ice for 40 minutes. Every 10 minutes, mix the buffer 
with pellet up and down.  
12. After 40 minutes on ice, use fridge centrifuge to spin down. 13.0 RCF for 30 minutes.  
13. Need 3 more eppendorf tube per sample. Add 100μL of each eppendorf tube into the 3 
eppendorf tube tubes after breaking up. 
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14. Now need filament buffer. Need 900μL of filament buffer for each eppendorf tube. Start 
by calculating how much buffer you need in total. Ratio is 1mM of EDTA to 0.1% BM in 
DDH20.  
15. Mix well and put in fridge on ice overnight. 
16. The following day: Take out of ice box and put Myofibrillar samples in fridge centrifuge. 
13.0 RCF for 30 minutes.  
17. Take buffer out and throw away. We want pellet. 
Empty one eppendorf tube fully. For other two empty all but 50μL. Scrape the eppendorf 
tube to get the pellet off and switch all into 1 eppendorf tube.  
18. Add 600μL of filament buffer to each eppendorf tube. Scrape pellet and mix well. 
19. Centrifuge 13.0 rcf for 3 minutes. 
20. Take out 600μL and throw away. 
21. Add 50μL of 1x sample buffer to each eppendorf tube, mix well.  
Appendix B - Immunofluorescence Microscopy 
1. Sterilize cover slips by autoclaving them. Place a single cover slip into each well of a 12-
well plate. 
2. Plate L6 myoblasts in the 12-well plate on top of cover slips. Include sufficient number of 
well so you can have a negative control. Grow myoblasts according to regular procedure. 
3. When cells are confluent, change to differentiation medium. 
4. Change medium every 24-48 hours until day 4 when myotubes are ready for treatment. 
On day 4, treat cells with the chemotherapy drug cocktail according to regular protocol. 
The following steps take place on both day 5 and day 6 of treatment. 
5. Remove medium and rinse each well 2X with 1mL of PBS. 
6. FIXING: In fume hood, fix cells by incubating them in 1mL/well of paraformaldehyde 
(4% PFA in PBS) for 10minutes at room temperature. Use gentle swirling on a rocker. 
After 10minutes, remove paraformaldehyde and store in a container in hood. 
7. Do 3X quick rinse in PBS with 1mL/well.  
8. PERMEABILIZATION: Permeabilize the cells by adding 1mL/well of 0.03% Triton X-
100 in PBS. Incubate for 5 minutes. 
9. WASHING: Remove Triton solution and wash 5X, 1mL/wash, 5minutes/wash. 
10. BLOCKING: Incubate with 400μL/well of blocking solution: 10% horse serum in PBS. 
Block at 37°C for 1hour with periodic swirl. 
11. PRIMARY ANTIBODY: Add sufficient amount of diluted antibody, ~500μL/well. 
(MHC from Dev Hybridoma, 2.5μg/mL diluted in 1% BSA in PBS). Incubate overnight 
at 4°C with gentle rocking. 
12. WASH: Decant and save primary antibody. Do one quick rinse in PBS and then 3X wash 
in PBS, 5minutes/wash with gentle rocking. 
13. SECONDARY ANTIBODY: Dilute secondary antibody (Texas Red anti-mouse IgG, 
raised in horse). Dilute 1:100 with 1% BSA in PBS. After removing PBS from washing 
(step 12), add 500μL/well of the diluted secondary antibody and incubate for 2hour, room 
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temperature on a rocker. Make sure to keep the wells covered and protected from light 
using aluminum foil. This is to ensure that no photo-damage takes place on the 
fluorochromes of the secondary antibody.  
14. WASH: Remove secondary antibody and wash 5X, 10minutes/wash in PBS. 
15. MOUNTING: Take appropriately labelled microsclope slides. Put a drop of mounting 
medium on each slide. The mounting medium contains DAPI (to stain the nucleus) and 
anti-oxidants to prevent oxidation of the fluorochromes.  
16. With a pair of tweezers, take the cover slip out and invert the slip on the mounting 
medium. Ensure the side on which the cells are face the medium. 
17. MICROSCOPY: Observe under the microscope.  
Appendix C - Deoxy-Glucose Uptake in Myotubes 
Following the 20minute insulin treatment: 
1. Aspirate media and do 2X wash with 400μL/well of Hepes Buffered Saline at room 
temperature. After 2X washes, aspirate any remaining media. 
HEPES BUFFERED SALINE: 
- 140 mM NaCI 
- 20 mM Hepes-Na, pH 7.4 
- 5 mM KCI 
- 2.5mM MgSO4 
- 1.0 mM CaCI2 
2. For specific uptake, add 300μL/well of transport solution/well of the 12-well plate. 
TRANSPORT SOLUTION: 
- Prepare in Hepes Buffer 
- 10μM 2-Deoxy-Glucose 
- 0.5 μCi/mL 3H 2-Deoxy-Glucose 
3. Incubate for 5minutes at room temperature. 
4. Working quickly, aspirate away the transport solution and do 3X washes, 1mL/well with 
ice-cold stop solution and aspirate to dryness. 
ICE-COLD STOP SOLUTION: 
- 0.9% Saline 
5. Add 1mL/well of 0.05 NaOH, scrape and add 800μL for scintillation counting. The 
remaining 200μL is collected for protein assay and stored at -20°C.  
 
 
 
